

1 **VALIDATION OF *IN VITRO* MODELS FOR SMOKE EXPOSURE OF PRIMARY HUMAN BRONCHIAL**  
2 **EPITHELIAL CELLS**

3 Michal Mastalerz<sup>1</sup>, Elisabeth Dick<sup>1</sup>, Ashesh Chakraborty<sup>1</sup>, Elisabeth Hennen<sup>1</sup>, Andrea C. Schamberger<sup>1</sup>,  
4 Andreas Schröppel<sup>1</sup>, Michael Lindner<sup>2,3</sup>, Rudolf Hatz<sup>4</sup>, Jürgen Behr<sup>5</sup>, Anne Hilgendorff<sup>1</sup>, Otmar  
5 Schmid<sup>1</sup>, and Claudia A. Staab-Weijnitz<sup>1\*</sup>

6 <sup>1</sup> *Institute of Lung Biology and Disease and Comprehensive Pneumology Center with the CPC-M*  
7 *bioArchive, Helmholtz Zentrum München, Member of the German Center for Lung Research (DZL),*  
8 *Munich, Germany*

9 <sup>2</sup> *Asklepios Fachkliniken München-Gauting, Munich, Germany*

10

11 <sup>3</sup> *Present address: University Department of Visceral and Thoracic Surgery Salzburg, Paracelsus*  
12 *Medical University, A-5020, Salzburg, Austria*

13 <sup>4</sup> *Thoraxchirurgisches Zentrum, Klinik für Allgemeine, Viszeral-, Transplantations-, Gefäß- und*  
14 *Thoraxchirurgie, Klinikum Großhadern, Ludwig-Maximilians-Universität (LMU), Munich, Germany*

15

16 <sup>5</sup> *Medizinische Klinik und Poliklinik V, Klinikum der Ludwig-Maximilians-Universität (LMU), Munich,*  
17 *Germany, Member of the German Center for Lung Research (DZL)*

18

19 \*To whom correspondence should be addressed:

20 Claudia Staab-Weijnitz, Comprehensive Pneumology Center, Ludwig-Maximilians-Universität and  
21 Helmholtz Zentrum München, Max-Lebsche-Platz 31, 81377 München, Germany, Tel.: 0049(0)89-  
22 31874681; Fax: 0049(89)31874661; Email: [staab-weijnitz@helmholtz-muenchen.de](mailto:staab-weijnitz@helmholtz-muenchen.de)  
23 ORCID-ID: <https://orcid.org/0000-0002-1211-7834>

24

25 **Running title:** Bronchial *in vitro* smoke exposure models

26

27 **Keywords:** Cigarette smoke, cigarette smoke extract, primary human bronchial epithelial cells,  
28 validation, *in vitro* smoke model, differentiation

29 **Summary**

30 **Rationale.** The bronchial epithelium is constantly challenged by inhalative insults including cigarette  
31 smoke (CS), a key risk factor for lung disease. *In vitro* exposure of bronchial epithelial cells using CS  
32 extract (CSE) is a widespread alternative to whole CS (wCS) exposure. However, CSE exposure  
33 protocols vary considerably between studies, precluding direct comparison of applied doses.  
34 Moreover, they are rarely validated in terms of physiological response *in vivo* and the relevance of  
35 the findings is often unclear. **Methods.** We tested six different exposure settings in primary human  
36 bronchial epithelial cells (phBECs), including five CSE protocols in comparison with wCS exposure. We  
37 quantified cell-delivered dose and directly compared all exposures using expression analysis of 10  
38 well-established smoke-induced genes in bronchial epithelial cells. CSE exposure of phBECs was  
39 varied in terms of differentiation state, exposure route, duration of exposure, and dose. Gene  
40 expression was assessed by quantitative Real-Time PCR (qPCR) and Western Blot analysis. Cell type-  
41 specific expression of smoke-induced genes was analyzed by immunofluorescent analysis. **Results.**  
42 Three surprisingly dissimilar exposure types, namely chronic CSE treatment of differentiating phBECs,  
43 acute CSE treatment of submerged basal phBECs, and wCS exposure of differentiated phBECs  
44 performed best, resulting in significant upregulation of seven (chronic CSE) and six (acute wCS, acute  
45 submerged CSE exposure) out of 10 genes. Acute apical or basolateral exposure of differentiated  
46 phBECs with CSE was much less effective despite similar doses used. **Conclusions.** Our findings  
47 provide guidance for the design of human *in vitro* CS exposure models in experimental and  
48 translational lung research.

## 49 INTRODUCTION

50 Cigarette smoke (CS) contributes to 8 out of 10 most common causes of death, which consequently  
51 translates to 7 million deaths worldwide every year (1-3). The lung, as the most important portal of  
52 entry, develops a range of serious pathologies in response to CS, including chronic obstructive  
53 pulmonary disease (COPD) which currently is ranked fourth among the most common global causes  
54 of death (4). The bronchial epithelium provides the main first line of defense against inhaled insults  
55 like CS, which consists of thousands of compounds distributed among the gas and particle phase of  
56 the smoke (5). It is a pseudostratified layer of cells consisting of different cell types, the major ones  
57 being ciliated, club, goblet, and basal cells. Cell composition changes throughout the  
58 tracheobronchial tract. Mucus producing goblet cells and submucosal glands are more abundant in  
59 the trachea and upper respiratory tree whereas the lower airways are more populated by club cells  
60 (6). Each cell type serves specific functions in the maintenance of a physical barrier or detoxification  
61 of potentially harmful substances: Basal cells are the main airway progenitor cells, giving rise to all  
62 cell types in the conducting airway epithelium. Ciliated and goblet cells together form the mucociliary  
63 escalator, which is essential for the removal of harmful inhaled particles. Club cells secrete  
64 surfactant, have been ascribed a role in detoxification of xenobiotics, act as progenitor cells for  
65 ciliated and goblet cells (7) and have the ability to dedifferentiate into basal cells upon injury (8).  
66 Organization and structure of the bronchial epithelium can be drastically altered in chronic lung  
67 disease and it is known that CS contributes to squamous cell metaplasia, goblet cell hyperplasia,  
68 decrease of the ciliated cell population (9) and increased epithelial permeability (10).

69 Experimental settings to study the response of the airways to CS *in vitro* vary greatly in the literature.  
70 For instance, lung epithelial cells used for this purpose range from the use of immortalized or tumor-  
71 derived cell lines, such as A549 (11), BEAS-2B (12, 13) or NCI-H292 (14) to primary human bronchial  
72 epithelial cells (phBECs)(9, 15). Cells can further be cultured under submerged (16) conditions or at  
73 the air-liquid interface (ALI). For the latter, it becomes even more complex, as an ALI culture model  
74 can be exposed to CS components from the basolateral (9) or the apical side (17, 18). CS can also be  
75 delivered in different ways. Very frequently, a cigarette smoke extract (CSE) is used, which represents  
76 a rather straightforward and easily applicable technique (12, 19-21). In some studies cells were  
77 starved prior to exposure (16), or CSE was administered repeatedly over an extended period of time  
78 in efforts to mimic a chronic exposure (9). As for acute exposures, the duration varied from 30 min  
79 (14) up to 72 h (22). Also whole cigarette smoke (wCS) exposure is frequently applied (23-25) and  
80 considered to best mimic physiological CS delivery (24). This type of exposure, however, requires a  
81 more sophisticated exposure set-up not available to many experimental lung research laboratories,  
82 which is likely why many investigators resort to the use of CSE (12, 19-21).

83 A common limitation of such human *in vitro* studies is that typically little is done to standardize or  
84 validate experimental models using CS. With few exceptions where ISO and Canada health  
85 standardized protocols for smoking conditions and regimen ISO 3308:2012 (24, 25) were put in place,  
86 usually the choice of CSE concentration or delivered amount of CS was based on cytotoxicity  
87 assessments only, rarely on *CYP1A1* expression (9), or on blood levels of nicotine and other CS  
88 components in smokers (22). In addition, the delivered CS dose is rarely assessed which makes it  
89 inherently difficult to directly compare findings between different research laboratories, as even for a  
90 defined number of standard cigarettes the corresponding 100% CSE concentration depends on  
91 operational parameters such as a method of the whole smoke generation and amount of medium  
92 used. Finally, the experimental CSE exposure models have not been comprehensively assessed in  
93 terms of physiologically relevant gene expression changes, even though distinct transcriptomic  
94 signatures in current smokers relative to non-smokers are known (24, 26-31).

95 Here, based on the available literature, we selected five independent transcriptomic datasets, where  
96 gene expression in current smokers was compared to non-smokers, namely GSE994 (32), GSE4498  
97 (33), GSE7895 (34), GSE20257 (35), and GSE52237 (36). Inclusion criteria for current smokers differed  
98 somewhat between these studies, but in four out of five studies current smokers were only included  
99 if they had no respiratory symptoms and normal pulmonary function tests: GSE994 (32), GSE20257  
100 (35), GSE52237 (36) and GSE4498 (33). Beane and colleagues in GSE 7895 (34) excluded current  
101 smokers with lung cancer or unknown lung cancer status, but otherwise did not specify the  
102 respiratory health status of the smokers. From these five data sets, we carefully extracted a set of 10  
103 genes, which we, for the purpose of this study, termed smoke exposure regulated genes (SERGs,  
104 Table 1). All SERGs were consistently significantly upregulated in all five data sets. Notably, we  
105 deliberately did not choose a combined set of the top 10 altered genes, but instead, included genes  
106 with very high (> 10; AKR1B10, CYP1A1, CYP1B1), high (> 5 and ≤ 10; ADH7, ALDH3A1, UCHL1) and  
107 moderate fold change (<5; AKR1C1, MUC5AC, NQO1, PIR, Table 1) in order to increase the dynamic  
108 range of our approach.

109 Here, we took advantage of these SERGs to standardize and validate different *in vitro* exposure  
110 models in terms of physiological response *in vivo*. For this comparison, we chose CSE exposure  
111 protocols and strategies typically used by the experimental lung research community and compared  
112 them with wCS exposure using a comparable dose. We tested acute exposure of submerged basal  
113 cells (21, 37, 38), acute basolateral (39) and acute apical exposure of differentiated pHBEcs (15, 40),  
114 here with and without prior starvation (16, 41, 42), and, finally, chronic basolateral exposure of  
115 differentiating cells at the ALI (9, 43). Even if basolateral exposure is much different from the  
116 physiological scenario, we have reported previously that this exposure model can recapitulate

117 smoke-induced changes like loss of barrier integrity and COPD-like changes in cell type composition  
118 (9). In addition, cell-delivered CS doses were quantified and compared to estimated doses of inhaled  
119 CS *in vivo*. Overall, we describe a novel strategy how *in vitro* cigarette smoke exposure models can be  
120 validated and standardized, which rests on two pillars: (1) Assessment of a physiologically highly  
121 relevant, human-derived gene expression signature for the smoking-induced response of the human  
122 airway, and (2) quantification of the cell-delivered dose facilitating the direct comparison of *in vitro*  
123 to *in vivo* doses received by smokers. This method was used to critically assess the physiological  
124 relevance of six acute and chronic *in vitro* models of smoking exposure of human primary bronchial  
125 cells, using cigarette smoke extract and whole smoke as current golden standards of cigarette smoke  
126 exposure.

127 **MATERIALS AND METHODS**

128 **Patient material**

129 Basal primary bronchial epithelial cells (phBECs) were obtained from either the CPC-M BioArchive at  
130 the Comprehensive Pneumology Center (CPC, six donors) or Lonza, Basel, Switzerland (three donors).  
131 PhBECs from the CPC-M BioArchive were derived from patients undergoing lung tumor resections  
132 and isolated from histologically normal regions adjacent to the resected lung tumors, who were  
133 either ex-smokers with a cessation period of >10 years or never smokers (Table S1), with similar size  
134 of small bronchi across donors. Upon treatment of bronchi with Pronase E, epithelial cells were  
135 carefully scraped with a scalpel, minced and filtered through a 70µm strainer to remove tissue  
136 pieces. To remove fibroblasts, cells were plated on uncoated plates for 3 hours. Afterwards, collected  
137 supernatant was transferred onto collagen I (C3867, Sigma Aldrich, Germany) coated plates and then  
138 cultured with PneumaCult™ Ex-Plus (Stemcell Technologies, 05041, Vancouver, Canada) with 1%  
139 Pen/Strep. Cells were expanded in passage 1 and then moved to liquid nitrogen storage until later  
140 use. PhBECs obtained from Lonza had been isolated from healthy self-reported non-smokers (2  
141 females, 49 and 52 years old, and one 13 year old male). After isolation, all samples tested negative  
142 for *Mycoplasma pneumonia*, were expanded to passage 1, collected in freezing medium, and finally  
143 moved to liquid nitrogen storage until later use. All participants had given written informed consent,  
144 and the study was approved by the local ethics committee (454-12) of the Ludwig-Maximilians  
145 University of Munich, Germany.

146 **Preparation of CSE**

147 The mainstream smoke of six filtered reference cigarettes 3R4F (Kentucky Tobacco Research and  
148 Development Center at the University of Kentucky; Lexington, KY) was bubbled through 100 ml ALI-  
149 medium (Stemcell Technologies, 05041, Vancouver, Canada) or BEBM™ (Lonza, CC-3170) without  
150 supplements. CSE generation was carried out at a flow rate of 0.3 l/min and the resulting medium  
151 considered as 100% CSE. CSE was then filtered through a 0.2 µm filter (Minisart; Sartorius Stedim  
152 Biotech), aliquoted and immediately stored at -80°C. For gravimetric analysis and CSE exposure,  
153 aliquots were later thawed and used immediately at the indicated concentrations.

154 **Determination of dose by gravimetric analysis**

155 200µl of media used in experiments and media exposed to a cigarette smoke as described above was  
156 pipetted on Whatman® quartz filters (Sigma Aldrich) and placed inside a sealed desiccator until  
157 completely dry. The weight of the filters was measured before and after medium application. The  
158 difference between CSE-free and 100% CSE medium yielded the CS dose in 200 µl 100% CSE and was  
159 used for dose calculations for all CSE exposures.

## 160 **Primers and antibodies**

161 Primers were obtained from Eurofins Genomics Germany GmbH (Ebersberg, Germany) and are listed  
162 in Supplementary Table S2. Supplementary Tables S3 and S4 contain the primary and secondary  
163 antibodies used in this study, respectively.

## 164 **Primary bronchial epithelial cell cultivation and differentiation**

165 For expansion, cells derived from BioArchive and Lonza were thawed at passage 1 and seeded at a  
166 density of 20,000-25,000 cells/cm<sup>2</sup> on 100 mm plates (Corning, 430167, New York, USA) using BEGM  
167 Bronchial Epithelial Cell Growth Medium BulletKit (Lonza CC-3170, containing: BEBM™ Clonetics  
168 Medium (CC-3170) + SingleQuots Supplements and Growth Factors (CC-4175)) + 100U Pen/Strep (Life  
169 Technologies, 10,000 U, 15140) or PneumaCult™ Ex-Plus (Stemcell Technologies, 05041, Vancouver,  
170 Canada) with 1% Pen/Strep. BEGM was used for expansion and acute submerged exposure of basal  
171 cells, in agreement with our previous studies (21, 44). In contrast, for all exposure types involving  
172 differentiation or differentiated cells, cells were expanded in PneumaCult™ Ex-Plus before  
173 differentiation at ALI. Upon reaching 80-90% confluency, cells were seeded on 12-well transwells  
174 (Corning, 3460, 12mm inserts, Polystyrene, 12-well plate, 0.4µm Polyester Membrane, Tissue Culture  
175 Treated, 1.12cm<sup>2</sup>/transwell), coated with collagen IV (C7521, Sigma Aldrich, Germany) seeding  
176 100,000 cells per membrane. The cells were air-lifted after reaching 100% confluency in 1-3 days and  
177 medium was changed to ALI-medium (PneumaCult™-ALI Medium, Stemcell Technologies, 05002 with  
178 added supplement (05003) and additives (05006)) and left for differentiation at the air-liquid  
179 interface for 28 days, with media changed every 2 days. Throughout the experiments, cells were  
180 cultured at 37°C in a humidified cell incubator with 95% air and 5% CO<sub>2</sub>.

## 181 **Transepithelial Electrical Resistance (TEER) Measurements**

182 After adding apically pre-warmed HBSS (Lonza, CC-5024) onto inserts, cells were left to equilibrate at  
183 room temperature for at least 10 min. The TEER measurements were performed in triplicates for  
184 each insert, using a Millicell-ERS-2 volt-ohm-meter (Millipore, Billerica, MA) with a STX01 chopstick  
185 electrode (Millipore). For all treatment conditions, at least three individual wells per donor were  
186 analyzed. After measurement, the blank value (a similar measurement of a cell-free insert) was  
187 subtracted and the resulting value multiplied by the well surface area (1.12 cm<sup>2</sup> for 12-well transwell  
188 inserts from Corning) to yield  $\Omega \times \text{cm}^2$ .

## 189 **Cigarette smoke exposure models**

190 All cigarette smoke exposure models were performed in four to five independent experiments using  
191 pHBEs derived from independent donors from the CPC BioArchive. In total, cells from six donors

192 were used and there was an overlap of at least three donors in all exposure models (Supplemental  
193 Table S1). Lonza cells were only used in addition for submerged acute basal cell exposure, taking  
194 advantage of samples already available from our previous study (21).

#### 195 **Acute submerged exposure of basal cells with CSE**

196 Acute submerged exposure of basal cells with CSE was done as described previously (21). Briefly,  
197 after reaching 80%-90% confluency on a 100 mm dish cultured in BEGM, cells were washed in HBSS  
198 (Lonza, CC-5024) and then trypsinized using Trypsin with EDTA (Lonza, CC-5012). Reaction was  
199 stopped by Trypsin inhibitor TNS (Lonza, CC-5002). PhBECs were then centrifuged at 400 g for 5 min,  
200 the supernatant carefully removed and the cell pellet resuspended in BEGM medium, followed by  
201 counting in a CASY cell counter (OLS-OMNI Life Science, Bremen, Germany). The cells were then  
202 seeded on 6-well plates (TRP, 92406, 9,6cm<sup>2</sup>/well) at a density of 1.0 x 10<sup>4</sup> cells/cm<sup>2</sup>, cultured 3 days  
203 until confluency, and finally exposed to the indicated CSE concentrations for 24 h. Prior to mRNA or  
204 protein extraction, cells were washed twice with ice-cold HBSS and stored at -80°C.

#### 205 **Chronic and acute basolateral exposure with CSE**

206 PhBECs were expanded in PneumaCult™ Ex-Plus Medium on 100 mm dishes and subsequently  
207 seeded on 12-well transwell plates. Upon reaching 100% confluency in the inserts, cells were air-  
208 lifted (= day 0) and the basolateral medium was immediately changed to either ALI or 5% CSE in  
209 PneumaCult™-ALI medium, as described in (9). During the full differentiation period of four weeks,  
210 5% CSE or PneumaCult™-ALI medium was regularly exchanged every two days. Every 7 days from  
211 airlift until day 28, inserts were either collected and stored in -80°C, or fixed in PFA for  
212 immunofluorescent (IF) analysis.

213 Acute basolateral CSE exposure was carried out on differentiated phBECs on day 28 after airlift. Here,  
214 cells were exposed to 5% CSE in the basolateral part for 24 h, after which cells were washed twice in  
215 ice-cold HBSS and stored at -80°C.

#### 216 **Acute apical exposure with CSE**

217 Fully differentiated phBECs were treated for 24 h with 200µl of 3%, 6% or 12% of CSE from the apical  
218 side, followed by subsequent collection of cells, apical washes and media. In the experiment  
219 including starvation, cells were starved in PneumaCult™-ALI medium without supplements 24 h prior  
220 to the treatment, followed by the identical exposure and collection, as described above. As a control,  
221 a mock exposure with only PneumaCult™-ALI was used.

222 For direct comparison with exposure to whole cigarette smoke (see below), cells were treated 5 min  
223 with 200µl of 40% CSE added apically, followed by careful removal of the CSE without washing with  
224 HBSS, and incubation for 24 h at 37°C. Subsequently, cells were washed twice with ice cold HBSS and  
225 then stored at -80°C, along with apical washes and basolateral medium.

#### 226 **Air-Liquid Interface Cell Exposure with Whole Cigarette Smoke (ALICE-Smoke)**

227 Transwell inserts with and without fully differentiated phBECs were put into the pre-warmed 12-well  
228 plate in the ALICE-Smoke chamber which is a 12-well insert adapted version of the stagnation flow  
229 system described previously (45, 46). For dosimetry three to four 1.1 cm<sup>2</sup> metal plates were placed on  
230 three to four cell-free inserts. Then, 800 µl of pre-warmed PneumaCult™-ALI medium was added to  
231 the basolateral side of the transwell inserts. After tight assembly of the pre-warmed smoke chamber  
232 (Supplementary Figure S1; all Supplemental material is available at  
233 <https://figshare.com/s/35a9228cd52d702ef622>), it was placed into an incubation chamber (37°C)  
234 and inserts were exposed to a continuous flow of cigarette smoke, generated by burning 3 cm of  
235 filtered Research-grade cigarettes at a total flow rate of 0.6 L/min for about 2 min (0.05 L/min per  
236 transwell), followed by exposure to sterilized air for further 2 min. To measure the cell-delivered  
237 dose, the metal plates located in the inserts during exposure were collected in Falcon tubes and the  
238 deposited smoke components were dissolved in 1 ml absolute ethanol. Also the quartz filter located  
239 just downstream of the 12-well plate, which collects all of the smoke not deposited in the exposure  
240 chamber (>95% of total smoke (45, 47); Supplementary Figure S1), was placed in tightly closed plastic  
241 container with silica gel, dried for 2 h at room temperature, and weighed before and after exposure  
242 using an analytical balance to obtain the total smoke mass on the filter ( $M_{tot}$ ). Next, the cigarette  
243 smoke components on the quartz filter were dissolved in 20 ml of absolute ethanol and the resulting  
244 solution with a known smoke concentration ( $M_{tot} / 20$  ml) was diluted 1:50. The cell-delivered  
245 cigarette smoke dose was determined by quantitative fluorescence analysis of all alcohol extracts  
246 ( $\lambda_{exc}$  355 nm,  $\lambda_{em}$  460 nm; Safire II Plate reader, Tecan, Männedorf, Switzerland). Measurements were  
247 carried out on Greiner 96-well microplate (Sigma-Aldrich, 655101, St. Luis, USA) in four technical  
248 replicates, using 99 % ethanol as a blank. Finally, based on the known weight and fluorescence of the  
249 deposited smoke dose on the outlet quartz filter, the dose deposited on each metal plate was  
250 calculated from the fluorescence intensity of the corresponding alcohol extract.

#### 251 **RNA Isolation and Real-Time Quantitative Reverse-Transcriptase PCR (qRT-PCR) Analysis**

252 For RNA extraction from phBECs, the RNeasy Mini Plus Kit (Qiagen, 74136, Venlo, Netherlands) was  
253 used according to the manufacturer's instructions. RNA concentration was determined measuring  
254 absorbance in a NanoDrop 1000 spectrophotometer (NanoDrop Tech. Inc; Wilmington, Germany) at

255 260 nm. Next, RNA was reverse transcribed to cDNA using reverse transcriptase (Applied Biosystems,  
256 N8080018, Waltham, USA or Invitrogen, 28025013) and random hexamer primers (Applied  
257 Biosystems). For this, 1 µg RNA was diluted up to 20 µl with DNase/RNase free water, denatured at  
258 70°C for 10 min and then incubated on ice for 5 min. 20 µl of cDNA synthesis master mix (5 mM  
259 MgCl<sub>2</sub>, 1x PCR buffer II (10x), 1 mM dGTP, 1 mM dATP, 1 mM dTTP, 1 mM dCTP, 1 U/µl RNase  
260 inhibitor, and 2.5 U/µl MuLV reverse transcriptase) was added to each sample and cDNA synthesis  
261 was performed for 60 min at 37°C, followed by 10 min incubation at 75°C. cDNA was diluted up to  
262 200 µl with DNase/RNase-free water for usage in qRT-PCR analysis. qRT-PCR was performed in 96-  
263 well format using a Light Cycler® LC480II instrument (Roche) and LightCycler® 480 DNA SYBR Green I  
264 Master (Roche). Fold changes relative to control were calculated as  $2^{-\Delta\Delta C_t}$  with  $\Delta\Delta C_t = \Delta C_t$  (exposure) -  
265  $\Delta C_t$  (mock), where  $\Delta C_t = C_t$  (gene of interest) -  $C_t$  (reference) for each condition. For specific gene  
266 amplification, primers listed in Supplementary Table S2 were used. For each exposure type, the most  
267 stable internal reference gene out of four (DHX8, WDR89, GADPH or HPRT) was determined and then  
268 used for standardization of relative mRNA expression. Gene expression changes were always similar  
269 for two independent internal reference genes. All qRT-PCR reactions were performed in technical  
270 duplicates and non-template controls were included for quality control.

#### 271 **Protein Isolation, SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) and Immunoblotting**

272 For protein isolation, cells were placed on ice, washed twice in ice-cold HBSS and scraped into 80 µl  
273 RIPA buffer (50 mM Tris•HCl, pH 7.6, 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate,  
274 and 0.1% SDS) with Complete™ protease inhibitor cocktail (05892970001, Roche, Basel, Switzerland)  
275 and PhosSTOP™ phosphatase inhibitor cocktail (PHOSS-RO, Roche) with either a cell scratcher or a  
276 1 ml pipette tip. The wells or inserts were washed once with an equal amount of RIPA buffer and  
277 transferred to the same tube. After incubation on ice for 30 min, tubes were centrifuged at 4 °C for  
278 15 min at 14,000 RPM. Supernatants were collected and stored at -80°C. Protein concentration was  
279 determined using the Pierce™ BCA Protein Assay Kit (23225, Thermo Scientific, Rockford, USA)  
280 according to manufacturer's instructions.

281 For SDS-PAGE, samples were denatured with Laemmli buffer (65 mM Tris-HCl pH 6.8, 10% glycerol,  
282 2% SDS, 0.01% bromophenol blue, 100 mM DTT) and separated on 10% or 12% polyacrylamide gels.  
283 Proteins were transferred to polyvinylidene difluoride (PVDF) membranes (Thermo Scientific, 88518,  
284 Rockford, USA) using a wet tank blotting system (Mini PROTEAN® Tetra Cell, 552BR, Bio-Rad, Munich,  
285 Germany). After blocking for at least 30 min in 5% skimmed milk in TBS-T (0.1% Tween 20, TBS),  
286 membranes were washed three times for 10 minutes in TBS-T and incubated with primary antibody  
287 (see Supplementary Table S3) overnight at 4 °C. After washing three times for 10 min in TBS-T,  
288 membranes were incubated at room temperature with secondary antibodies (see Supplementary

289 Table S4), followed by visualization with SuperSignal™ West Pico, SuperSignal™ West Dura or  
290 SuperSignal™ West Femto Maximum Sensitivity Substrate, according to the intensity of the detected  
291 signals (all Thermo Fisher Scientific, 34079, 37071, 34095, respectively) and analyzed by the  
292 ChemiDocXRS+ imaging system (Bio-Rad, Munich, Germany).

### 293 **Cytotoxicity Assay**

294 After each exposure, the apical and basolateral supernatants were collected and stored at -80 °C.  
295 After preparing high control by lysing cells in 2% Triton-X/media/0% FCS, the supernatants were  
296 centrifuged at 250 g for 10 min. The supernatants in each tube were carefully collected and then  
297 30 µl of the supernatants were pipetted into a Greiner 96-well microplate (Sigma-Aldrich), followed  
298 by quantification of lactate dehydrogenase (LDH) release using the cytotoxicity detection kit (LDH ,  
299 11644793001, Sigma-Aldrich) according to manufacturer's instructions.

### 300 **Immunofluorescence Analysis**

301 PhBECs were stained on the transwell membrane and the different cell types quantified as described  
302 previously (44). Following the indicated treatment, phBECs were washed twice in HBSS and fixed  
303 from the apical and basolateral side with 3.7% paraformaldehyde (PFA) overnight at 4 °C or 1 h at  
304 room temperature. After aspirating PFA, the inserts were washed in 1x PBS and then either stored at  
305 4 °C until usage or immediately permeabilized with 0.2% Triton X-100/PBS for 5 min. The inserts were  
306 then again washed with PBS and blocked with 5% BSA/0.2% Tween/PBS for 1 h at room temperature.  
307 PhBECs were stained directly on the transwell membrane after cutting into quarters or six pieces  
308 using a scalpel. Membrane fragments were transferred to a 24-well plate and the appropriate  
309 primary antibody was applied (see Supplementary Table S3), diluted in 5% BSA/0.2% Tween/PBS for  
310 1h at room temperature or overnight at 4°C (volume: 150 µl). Afterwards, membranes were washed  
311 three times with PBS for 5 min. Then, the secondary antibody conjugated with either Alexa Fluor 488  
312 or Alexa Fluor 568 (see Supplementary Table S4) diluted in the same buffer was applied and  
313 incubated for 30 min at room temperature protected from light by aluminum foil. Nuclei were  
314 stained with 0.5 µg/ml 4,6-diamidino-2-phenylindole (DAPI) at 1:2000 dilution. Membranes were  
315 again washed three times in PBS, mounted in fluorescent mounting medium (Dako, S3023, Hamburg,  
316 Germany) and dried overnight at room temperature. Fluorescent microscopy was performed using  
317 an upright microscope (Axiovert II; Carl Zeiss AG; Oberkochen, Germany). Images were processed  
318 using ZEN 2010 software (Carl Zeiss AG) or Imaris 7.4.0 software (Bitplane; Zurich, Switzerland).  
319 Immunofluorescence quantification was performed using Imaris 7.4.0 software (Bitplane). For this, z-  
320 stack images of stained transwell membranes were obtained by fluorescent microscopy and 1500 –

321 4500 cells per image were analyzed for positivity of specific markers, largely as described  
322 previously (9).

323 **Statistical Analysis**

324 Results are depicted as mean  $\pm$  SD and derived from at least four independent experiments, where  
325 each experiment was performed with cells from a different donor. All data sets were tested for  
326 normal Gaussian distribution using the Shapiro-Wilk test. Data distribution was normal for all  
327 experiments with single comparisons, *i.e.* wCS, acute apical 40% CSE, and basolateral acute 5% CSE  
328 exposure. For these, we used a paired, two tailed student's *t*-test. Distribution of a few data sets in  
329 submerged basal CSE, acute apical CSE, and basolateral chronic CSE exposure was not normal.  
330 However, as tests for normal distribution are insensitive to small sample sizes, we nevertheless used  
331 parametric test methods, which are more suitable for very small sample sizes, accepting the risk that  
332 the assumption of normal distribution may not be met in all cases. Accordingly, repeated measures  
333 ANOVA with Bonferroni correction was used for all multiple comparisons. Notably, using non-  
334 parametric testing for the few data sets, which were not normally distributed (Friedman test with  
335 Dunn's correction), did not change the overall results: Statistical significance was reached for the  
336 same genes, albeit with higher p-values reflecting the lower statistical power of the non-parametric  
337 test.

338 For comparing baseline expression of AhR-responsive SERGs (supplemental Figure S2) a non-  
339 parametric Friedman test with Dunn's correction was used, while significance between donors in  
340 baseline expression levels of SERGs (supplemental Figure S3) was tested by using one-way ANOVA  
341 with Bonferroni correction. CSE gravimetric measurements (supplemental Figure S4) significance was  
342 assessed by using unpaired two tailed student's *t*-test. This information is also given in the figure  
343 legend and where applicable. All statistical calculations were carried out in GraphPad Prism 8  
344 Software (San Francisco, CA). Significance levels: \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$  \*\*\*\* $p < 0.0001$ .

345

## 346 **RESULTS**

### 347 **Quantitative analysis of cigarette smoke mass allows for direct dose comparisons between** 348 **different experimental models**

349 To facilitate comparison of cell-delivered dose between CS exposure models, the mass of cigarette  
350 smoke contained in CSE and the smoke mass deposited on the cells during whole smoke exposure  
351 were experimentally determined. Briefly, 200  $\mu$ l of 100% CSE and CSE-free medium were pipetted  
352 onto separate quartz filters, and, after complete drying, the CSE mass was determined by gravimetric  
353 analysis. CSE was generated in two different media using identical settings described above, resulting  
354 in very similar CSE concentrations (PneumaCult<sup>TM</sup>-ALI medium: 1.40 mg/ml; BEGM medium:  
355 1.25 mg/ml) (Supplementary Figure S4). From the known dilution of CSE in and the volume of cell  
356 culture medium supplied to the cells, the mass of CSE per exposed cell area could be calculated for  
357 each CSE exposure scenario.

358 For determining the mass of whole CS deposited on each insert in the ALICE-Smoke system, metal  
359 plates were placed in unoccupied inserts and a gravimetrically known mass of whole CS was collected  
360 on a quartz filter downstream of the ALICE-Smoke exposure chamber. After performing quantitative  
361 spectrofluorometry on alcohol extracts from both the plates and the filter, the mass dose in all CSE  
362 exposure models could be calculated as the total mass of cigarette smoke applied per area of the  
363 exposed cell layer area (Table 2).

### 364 **Differentiation of phBECs was successful**

365 Immunofluorescent stainings for p63, acetylated tubulin, CC10 and MUC5AC at day 0, 7, 14, 21 and  
366 28 of differentiation showed successful generation of all major cell types at the expense of basal  
367 cells, with percentages that resemble the physiological cell type composition in larger airways (48-50)  
368 (Figure 1 B, C). TEER is a measure of cell adhesion and epithelial cell junctions' integrity (51). Weekly  
369 measurements demonstrated the establishment of an intact epithelial barrier early during the  
370 differentiation procedure (Figure 1D). TEER showed considerable donor variability, in particular at  
371 early time points, while levels were highly consistent after 4 weeks of differentiation. The  
372 immunofluorescence pictures, along with quantification of cell types indicate differentiation of basal  
373 cells into a full-blown bronchial epithelium with all main cell types.

### 374 **Cells were exposed to non-toxic doses of cigarette smoke**

375 In order to evaluate cytotoxic effects of CS, LDH and TEER measurements were carried out following  
376 each exposure. The post-exposure LDH release and TEER values were not significantly different from  
377 the controls for whole cigarette smoke (wCS, ALICE-Smoke) and apical CSE exposure (Supplementary

378 Figure S5), while basolateral exposure with the same CSE concentrations has been established as  
379 non-toxic previously, both for basal phBECs and fully differentiated phBECs (9, 21, 44). Both TEER and  
380 LDH data showed that phBECs were exposed to non-toxic doses of smoke.

### 381 **Response of phBECs to CS strongly depends on exposure type and cell composition**

382 In total, six different CS exposure settings were evaluated in terms of expression of 10 smoke  
383 exposure regulated genes (SERGs) (Table 1). Notably, for all of these exposures we used phBECs from  
384 at least four donors isolated under standardized conditions from the same source (Table S1). Of  
385 these, the following three settings were comparably effective in upregulation of SERGs on transcript  
386 level: Submerged acute exposure of basal cells with CSE upregulated six SERGs (*AKR1B10*, *AKR1C1*,  
387 *CYP1A1*, *NQO1*, *PIR*, *UCHL1*); chronic basolateral exposure with CSE during the complete period of  
388 differentiation upregulated seven SERGs (*AKR1B10*, *AKR1C1*, *ALDH3A1*, *CYP1A1*, *CYP1B1*, *NQO1*, *PIR*);  
389 and ALICE-Smoke CS exposure upregulated six SERGs (*AKR1B10*, *AKR1C1*, *CYP1A1*, *CYP1B1*, *NQO1*,  
390 *UCHL1*). In contrast, acute apical and basolateral exposure to various concentrations of CSE did not  
391 alter the expression of more than one gene (Table 3). The specific results are described in more detail  
392 in the following.

#### 393 *Submerged exposure of basal cells with CSE upregulates six out of nine possible SERGs*

394 One SERG, MUC5AC, is a goblet cell specific protein and was thus, as expected, not expressed by  
395 basal cells (data not shown). Out of the remaining nine SERGs, qRT-PCR analysis demonstrated  
396 significant upregulation of six (*AKR1B10*, *AKR1C1*, *CYP1A1*, *NQO1*, *PIR*, *UCHL1*), when  
397 undifferentiated basal cells were exposed to CSE under submerged conditions (Figure 2A, B).  
398 Upregulation was dose-dependent for *AKR1B10*, *UCHL1*, *NQO1*, *AKR1C1* and *PIR*, but not for *CYP1A1*.  
399 Unexpectedly, *ADH7* transcript levels were significantly reduced. In addition, we took advantage of  
400 samples from previously performed experiments (21) with cells purchased from Lonza  
401 (Supplementary Figure S6, n=3), where we even observed upregulation of all SERGs except for *ADH7*  
402 which again was significantly and dose-dependently reduced in those cells. This demonstrates that  
403 upregulation of SERGs in this model is a robust finding, independent of cell sources. The results from  
404 all seven donors were not pooled in order to provide better comparability between the models, as  
405 the commercially available cells had only been used for this exposure setting. For selected SERGs, we  
406 also assessed regulation on the protein level. Similar to the transcript data, we observed a dose-  
407 dependent increase of *AKR1B10*, *AKR1C1*, and *NQO1* protein (Figure 2C). Also *ALDH3A1* protein was  
408 upregulated in a dose-dependent manner in all three experiments, unlike to what we observed on  
409 transcript level (Figure 2B and C). In contrast, the commercially available cells failed to upregulate

410 ALDH3A1 on protein level, even though upregulation of ALDH3A1 was significant on transcript level  
411 (Supplementary Figure S6).

#### 412 *Chronic basolateral exposure with CSE during differentiation upregulates seven out of ten SERGs*

413 Here, cells were continuously treated with 5% CSE basolaterally for 28 days, *i.e.* throughout the  
414 entire differentiation, similar to the set-up used in Schamberger *et al* (9) (Figure 3A). The treatment  
415 resulted in trends for lower TEER values (Figure S7A), increased basal cell populations and decreased  
416 number of ciliated cells, all of which, however, failed to reach significance (Figure S7B). In contrast to  
417 our previous findings, numbers of goblet and club cells were not affected by 5% CSE. The RT-qPCR  
418 analysis demonstrated significant upregulation of seven out of 10 SERGs (*AKR1B10*, *AKR1C1*,  
419 *ALDH3A1*, *CYP1A1*, *CYP1B1*, *NQO1*, *PIR*, Figure 3B). Upregulation of *CYP1B1* and *CYP1A1* was dramatic  
420 (up to and more than 10-fold, respectively) in comparison to the remaining SERGs with moderate  
421 fold changes around +2. Upregulation of *AKR1B10*, *NQO1* and *ALDH3A1* was confirmed on protein  
422 level by Western blot analysis (Figure 3C).

#### 423 *Exposure with whole cigarette smoke (wCS) upregulates six out of ten SERGs, but with markedly* 424 *higher fold changes*

425 Here, in efforts to better mimic physiological exposure, fully differentiated phBECs were exposed to  
426 wCS using the ALICE-Smoke device (Figure 4A, Supplementary Figure S1). Expression of six out of 10  
427 SERGs was significantly upregulated (*AKR1B10*, *AKR1C1*, *CYP1A1*, *CYP1B1*, *NQO1*, *UCHL1*, Figure 4B)  
428 and confirmed on protein level for *AKR1B10*, *AKR1C1*, and *NQO1* (Figure 4C). Similar to the transcript  
429 data, *ALDH3A1* was not consistently upregulated on protein level either. Notably, for *CYP1A1*,  
430 *CYP1B1* and *UCHL1*, the observed upregulation fold changes were by magnitudes higher than in the  
431 other exposure models. Also *AKR1B10* and *AKR1C1* were upregulated more than 5-fold, while *NQO1*  
432 showed similar upregulation as in the above described exposure models. Unexpectedly, expression of  
433 *MUC5AC* was significantly downregulated.

#### 434 *Acute CSE exposures on differentiated cells have substantially lower influence on SERGs*

435 As the ALICE-Smoke system allows for quantification of the cell-delivered CS dose per area of  
436 exposed cell layer ( $\mu\text{g}/\text{cm}^2$ ), we additionally performed an experiment where we exposed the cells in  
437 parallel experiments from the apical side to a high non-toxic dose of CSE. Based on the gravimetric  
438 measurements (Supplementary Figure S4), 40% CSE corresponded to a dose of  $100 \mu\text{g}/\text{cm}^2$ , which  
439 was about 8 times higher than the determined CS deposition by wCS ( $12 \pm 1.5 \mu\text{g}/\text{cm}^2$ ). CSE was  
440 applied for 5 min, similar to the time wCS was applied in ALICE-Smoke. Notably, in sharp contrast to

441 the exposure by direct smoke, this exposure type failed to upregulate any of the reference genes  
442 (Figure 4).

443 Apart from this direct comparison with wCS, apical CSE exposures were also assessed in other  
444 settings: Acute apical exposure (Figure 5A) using 3%, 6% and 12% CSE for 24 h corresponded to CS  
445 doses of 7.5, 15 and 30  $\mu\text{g}/\text{cm}^2$ , very similar to the 12 $\mu\text{g}/\text{cm}^2$  determined for wCS. Here, only *CYP1A1*  
446 was significantly upregulated (Figure 5B), and starvation prior to exposure did not increase the  
447 number of upregulated SERGs, also only resulting in significant upregulation of *CYP1A1*  
448 (Supplementary Figure S8).

449 CSE was applied in acute manner also basolaterally, where cells were treated with 5% CSE for 24 h  
450 (Figure 6A). In contrast to chronic treatment, here only *CYP1A1* was significantly upregulated,  
451 similarly to the 24 h apical treatments (Figure 6B). Negative results for ALDH3A1, AKR1B10, AKR1C1  
452 and NQO1 were confirmed on protein level (Figure 6C).

453

#### 454 **Immunofluorescence analysis shows expression of SERGs by basal and luminal cell types**

455 As exposure of basal cells alone had resulted in induction of as many SERGs as wCS exposure, we  
456 hypothesized that basal cells are the main expressers of SERGs. To address this question in a model,  
457 which features a substantial smoke response and contains all major cell types, we chose wCS  
458 exposure and assessed colocalization of 4 selected SERGs (AKR1C1, NQO1, PIR and UCHL1) with  
459 markers of all major bronchial cell types. As expected, immunofluorescence analysis revealed  
460 upregulation of SERG-positive cells upon wCS exposure (Figure 4D). Moreover, all 4 SERG proteins  
461 assessed showed some colocalization with p63, a specific marker for basal cells (Figure 7).  
462 Nevertheless, NQO1, PIR and UCHL1 were mostly expressed by ciliated cells, as judged from  
463 colocalisation with acetylated tubulin (acTub, Figure 7, Supplementary Figure S9). In contrast,  
464 AKR1C1 colocalized mostly with the club cell-specific marker CC10 and not with the ciliated cell  
465 marker acTub. Very little colocalization was observed for the selected SERGs with MUC5AC, the  
466 marker for goblet cells.

467 **DISCUSSION**

468 In the present study, we defined a set of smoke-related reference genes (the SERGs, Table 1), based  
469 on known expression changes in current versus non-smokers, for validation of the physiological  
470 relevance of human *in vitro* smoke exposure models. Using phBECs, we assessed SERG expression in  
471 six different cigarette smoke exposure models (Table 2): (1) Acute submerged basal cell CSE exposure  
472 (Figure 2), (2) chronic basolateral exposure of differentiating phBECs with CSE (Figure 3), (3) acute  
473 apical exposure of differentiated phBECs with CSE (Figure 5 and Supplementary Figure S8), (4) acute  
474 basolateral exposure of differentiated phBECs with CSE (Figure 6), (5) and short acute apical exposure  
475 of differentiated phBECs with CSE in direct comparison with (6) apical exposure to wCS (Figure 4). No  
476 *in vitro* exposure model resulted in upregulation of all 10 SERG, but three surprisingly dissimilar  
477 exposure types, namely acute CSE treatment of basal submerged phBECs, chronic CSE treatment of  
478 differentiating phBECs, and wCS exposure of differentiated phBECs were similarly effective,  
479 upregulating six to seven SERGs. The other three CS exposure models were much less representative  
480 of the clinically observed gene regulation profile (<2 out of 10 SERGs) in spite of similar cell-delivered  
481 doses of CS used.

482 The current state-of-the-art of CS exposure, wCS, is available to few laboratories worldwide, which is  
483 why many investigators in experimental and translational lung research resort to simpler exposure  
484 settings as *e.g.* the use of CSE (12, 19-21). The preparation of CSE typically involves passing cigarette  
485 smoke through medium, where neither the number of cigarettes smoked nor the volume of medium  
486 used to capture the smoke nor the cigarette smoking regiment are standardized. Consequently, the  
487 generated 100 % CSE is not consistent throughout the literature (9, 52-54). On the other hand, when  
488 using whole cigarette smoke directly on cells, the dose of deposited cigarette smoke particulates  
489 typically remains unknown (55, 56) or is selected based on cell viability with unknown physiological  
490 relevance (57).

491 Here, we were able to experimentally determine the cell-delivered CS dose for both CSE and wCS  
492 exposure scenarios. This allowed not only for direct comparison of doses between different exposure  
493 settings, but also for an estimation how physiologically relevant the used dose is relative to *in vivo*  
494 exposure. For instance, it is known that approximately 82% of the inhaled smoke mass deposits on  
495 the 70 – 140 m<sup>2</sup> of lung epithelium (58, 59), and that the inhaled CS mass per smoked cigarette is  
496 about 10 mg (60). Notably, due to the physical properties of the bronchial airways, the impact of CS  
497 varies dependent on location in the bronchial tree and the main sites of CS particle deposition  
498 correlate with manifestation of lung diseases, such as lung cancer (61-63). Higher doses are possible  
499 at the airways' carinas of bifurcation, where the deposition can be increased up to 100-fold (64).  
500 Taken together, the theoretical maximal cigarette smoke (CS) mass per surface area and per cigarette

501 may thus be within the range of 0.59 – 1.17  $\mu\text{g}/\text{cm}^2$  in areas of high exposure like the  
502 aforementioned carinas of bifurcations. The CS doses we used in our exposure models (6 –  
503 100  $\mu\text{g}/\text{cm}^2$ ) were ca. 10 to 100-fold larger than the expected hot spot dose a smoker receives after  
504 smoking one cigarette (Table 2). It corresponds to the cumulative dose from 10 – 100 cigarettes. In  
505 many cases this represents the daily CS dose of a smoker, justifying the 24 h of incubation time  
506 chosen here for most of the *in vitro* experiments. In the direct comparison between CSE and wCS, an  
507 incubation time of 5 minutes with CSE was used (Figure 4). This was done in efforts to adapt an  
508 exposure duration similar to wCS exposure. Despite the fact that, here, the cells were intentionally  
509 not washed after aspiration of CSE, it is possible that they were not affected by the total dose of CSE  
510 applied due to the shorter exposure time on the one hand, but also due to possible scavenging of  
511 toxic compounds by free thiols or amines in the cell culture medium used to generate the CSE.  
512 However, the total dose was significantly higher ( $\approx 8$ -fold), so reasonable comparability may still be  
513 given for a fraction of the applied dose. In addition, wCS exposure can also directly be compared to  
514 apical CSE exposure for 24 h (Figure 5 and Supplementary Figure S8). In this case, however, air-liquid  
515 interface was compromised for the time of exposure, which is not a physiological scenario.  
516 Nevertheless, both systems had a strikingly lower effect on the cells as compared to wCS exposure.

517 The genetic expression profile of bronchial epithelial cells in current smokers varies greatly when  
518 compared to non-smokers (32-36). Here, we took advantage of this knowledge to test whether  
519 several human *in vitro* CS exposure models recapitulate smoke-induced expression changes *in vivo*.  
520 We carefully selected a set of 10 genes with substantial and consistent upregulation in smokers'  
521 epithelial cells (SERGS, Table 1) to validate various smoke exposure models (Table 2). The choice of  
522 CSE exposure models, which we directly compared to wCS exposure, was based on models widely  
523 used by the lung research community (9, 15, 16, 21, 65, 66). There were no significant differences in  
524 basal expression of all SERGs between never smokers and ex-smokers used in experiments  
525 (Figure S3).

526 The human bronchial epithelium is a pseudostratified layer of different cell types, which can be  
527 generated *in vitro* using primary bronchial epithelial cells cultured at the air-liquid interface. It is well  
528 established that cell type composition and gene expression can be dramatically altered by cigarette  
529 smoke, both *in vivo* (67, 68) and *in vitro* (9, 21, 65). However, to the best of our knowledge, no study  
530 has directly compared smoke-induced gene expression changes *in vivo* and *in vitro* in a more  
531 comprehensive manner. Previous studies, including our own, have used *CYP1A1* as a marker for the  
532 efficacy of CSE (9, 69) as *CYP1A1* expression is well known to be induced by polycyclic aromatic  
533 hydrocarbons (PAH) as *e.g.* benzo[a]pyrene and tetrachlorodibenzo-*p*-dioxin (TCDD), compounds  
534 which are highly abundant in cigarette smoke (70). This induction results from activation of the aryl

535 hydrocarbon (Ah) receptor which, after heterodimerization with the aryl hydrocarbon receptor  
536 nuclear translocator (ARNT) protein, binds to the xenobiotic responsive element (XRE) of the *CYP1A1*  
537 promoter and activates gene transcription (71). Notably, except for acute high-dose exposure with  
538 40% CSE, all of our exposure models resulted in upregulation of *CYP1A1*, implying that *CYP1A1*  
539 induction is a robust indicator of exposure to CS components. However, at the same time it becomes  
540 apparent that *CYP1A1* induction is not representative for CS-induced gene regulation, as in two  
541 models it remained the only strongly affected gene of all 10 SERGs. Intriguingly, other SERGs known  
542 to be directly induced by canonical AhR signalling, namely *CYP1B1*, *NQO1*, and *ALDH3A1* (72, 73)  
543 were often not induced in parallel with *CYP1A1* and never with a similarly high fold change (Table 3).  
544 This may in part be due to different levels of constitutive expression because induction of genes with  
545 very low basal transcription may lead to much higher fold changes than induction of genes that show  
546 considerable basal expression. Indeed, basal *CYP1A1* expression in all exposure models was much  
547 lower than the other AhR-responsive SERGs *CYP1B1*, *NQO1*, and *ALDH3A1* (Supplementary Figure  
548 S2). However, this also indicates that mechanisms other than direct canonical AhR signalling are  
549 important in this context and that it therefore is not sufficient to rely on *CYP1A1* induction for  
550 validation of the efficacy of CS exposure.

551 Importantly, AhR signalling also leads to induction of nuclear factor erythroid 2 related factor 2  
552 (Nrf2) (74), in turn a potent inducer of a battery of antioxidant proteins including the SERGs ADH7  
553 (75, 76), AKR1B10 and AKR1C1 (77-79), ALDH3A1 (75), NQO1 (75, 80, 81), PIR (82) and probably also  
554 UCHL1 (83). With Nrf2 being an AhR target, Nrf2-mediated gene regulation is delayed, relative to the  
555 direct AhR response. In addition, *CYP1A1* produces reactive oxygen species (ROS) during its catalytic  
556 cycle (84) which also leads to an induction of Nrf2 signalling (85). Consequently, high *CYP1A1*  
557 induction, as a biomarker for potent AhR activation as well as a direct inducer of oxidative stress,  
558 should lead to subsequent induction of almost all SERGs in our exposure models. While this is likely  
559 to be true for wCS exposure, our remaining data does not demonstrate such a clear relationship. For  
560 instance, acute basolateral and apical exposure with CSE for 24 h resulted in clear upregulation of  
561 *CYP1A1*, but none or only few of the Nrf2-responsive genes. At the same time, induction of *CYP1A1* in  
562 submerged basal cells upon CSE treatment was comparably moderate but accompanied by induction  
563 of several Nrf2 target genes (Table 3).

564 Surprisingly, two SERGs, namely MUC5AC and ADH7, were not upregulated in any of the exposure  
565 models. In fact, *ADH7* and *MUC5AC* transcription was either not altered or even significantly  
566 downregulated. In our previous work, we observed an increase of MUC5AC<sup>+</sup> cells upon chronic  
567 basolateral exposure with 5 % CSE in phBECs, which, however, was also not accompanied by the  
568 corresponding change in transcript levels (9). In contrast, Di and colleagues found moderately

569 increased MUC5AC expression in response to CSE treatment (86). On the other hand, recent  
570 evidence even suggests that CSE exposure may downregulate *MUC5AC* expression via activation of  
571 Notch signalling in epithelial cells (87, 88). We speculate that components of the cell culture medium,  
572 optimized to sustain a fully differentiated bronchial epithelium, may mask some deleterious effects  
573 by CS. This could also be true for *ADH7*, which encodes class IV alcohol dehydrogenase, an enzyme  
574 known to be involved in retinol and first-pass ethanol metabolism in the gastric epithelium (89, 90).  
575 While little is known about regulation of *ADH7* itself, another retinol-oxidizing member of the alcohol  
576 dehydrogenase family, *ADH1C* (gene *ADH3*) is regulated by retinoic acid (91, 92), a typical component  
577 of bronchial epithelial cell media (93). Taken together, the components of commercially available  
578 media, allowing for optimal growth and maintenance of organotypic bronchial epithelia, are not  
579 disclosed and may mask some effects caused by inhaled toxins observed *in vivo*. Of note, it has been  
580 previously reported that the choice of medium can affect pHBE culture (94). Furthermore, the  
581 absence of an immune compartment and other minor bronchial epithelial cell types as *e.g.* tuft or  
582 neuroendocrine cells could also lead to discrepancies *in vivo* and *in vitro*. These clearly are limitations  
583 of all of our models.

584 According to our collective results, three surprisingly dissimilar exposure types, namely acute CSE  
585 treatment of basal submerged pHBEs, chronic CSE treatment of differentiating pHBEs, and wCS  
586 exposure of differentiated pHBEs, were comparably effective in CS response when counting the  
587 number of significantly induced SERGs (six or seven out of 10 SERGs, Figures 2, 3 and 4, Table 3).  
588 Importantly, this assessment is based on transcript levels only, the same readout on which our  
589 selection of SERGs was based on. We also assessed expression of some SERGs on protein level and  
590 overall found similar trends for upregulation, albeit often not as pronounced as on transcript level.  
591 Similar expression changes can be found to some extent in the literature for both CSE (9) and wCS  
592 (56). Notably, with this study, we show that the two CS exposure models we have used in previous  
593 studies, exposure of basal cells with CSE (21, 65) and chronic basolateral exposure with CSE (9) are  
594 among the three best *in vitro* models assessed here. In qualitative agreement with our previous  
595 studies (9), we observed trends for a reduction of TEER, for an increased basal cell population, and  
596 for a reduction of ciliated cells in response to chronic basolateral exposure to 5% CSE. However, none  
597 of these changes reached statistical significance and we did not either observe an effect on goblet or  
598 club cells as we had reported earlier (9). We believe this to be caused by two changes in the current  
599 set-up compared to our previous studies. Firstly, for all experiments involving differentiating or  
600 differentiated cells, we used a different expansion medium, namely PneumaCult™ Ex-Plus (Stemcell)  
601 versus previously BEGM (Lonza). A recent report has highlighted that different differentiation media  
602 have a strong effect on structural and functional properties of the differentiated bronchial epithelium  
603 (95). While the differentiation medium in our studies remained the same, we speculate that also the

604 use of a different expansion medium may have persistent effects on the differentiating cultures.  
605 Secondly, we used different cell sources and a different number of biological replicates in these  
606 studies: While in the present study, pHBEs were derived from histologically normal regions adjacent  
607 to lung tumors from non-smokers and ex-smokers and all five differentiations +/- CSE were  
608 performed with cells from independent donors, we had previously used commercial basal cells from  
609 Lonza, all from self-reported healthy non-smokers, and performed several independent  
610 differentiations from two biological replicates only. The approach used in the current study is  
611 associated with a considerable increase in biological variability, making it inherently more difficult to  
612 obtain statistically significant results.

613 Considering the amplitudes of gene expression changes, wCS exposure clearly represents the model  
614 with the highest sensitivity in acute responses (Figure 4, Table 3). But taken together, similar to wCS  
615 exposure, submerged basal cell and chronic exposure of differentiating cells to CSE can be proposed  
616 as models that also reasonably well recapitulate the most substantial gene expression changes seen  
617 in *in vivo* cigarette smoke exposure (Table 3). Regarding the general applicability of CS exposure  
618 models, wCS exposure requires a fairly sophisticated experimental set-up, which is not available to all  
619 research laboratories. In that case, submerged exposure of basal cells to CSE is a reasonably good  
620 and quick-and-easy-to-perform model, which does not require the use of differentiation media and  
621 long-term culture. For research questions that require the full cell type composition of a bronchial  
622 epithelium, chronic basolateral exposure may be the model of choice.

623 Interestingly, submerged basal cell exposure with CSE as well as chronic basolateral exposure, where  
624 again, in particular during the initial phase of differentiation, predominantly basal cells are in direct  
625 contact with the CSE-containing medium, were far more efficient in upregulating SERGs than apical  
626 and acute basolateral CSE exposure of fully differentiated pHBEs. We therefore hypothesized that  
627 basal cells have a pivotal role in the response to cigarette smoke and express SERGs. Hence, we  
628 assessed the cellular localization of AKR1C1, NQO1, PIRIN and UCHL1 in fully differentiated cells,  
629 using the most sensitive model, wCS exposure (ALICE-Smoke). Indeed, basal cells did express all  
630 SERGs assessed, but contributed relatively little to their overall expression. In fact, NQO1, PIR and  
631 UCHL1 were predominantly expressed by ciliated cells (NQO1, PIRIN, UCHL1), and AKR1C1 by club  
632 cells (Figure 7). In line with our results, NQO1 has been previously reported to be overexpressed in  
633 ciliated cells, where it may protect the bronchial epithelium, in particular the basal progenitor cells,  
634 from inhaled toxic substances and carcinogens (96, 97). Similarly, expression in basal and ciliated cells  
635 has been described for UCHL1 (98), a hydrolase associated with ubiquitin homeostasis, degradation  
636 of proteins (99), and cell apoptosis (100). In contrast to our results, AKR1C1, an aldo-keto reductase  
637 responsible for breaking down toxic aldehydes widely present in tobacco smoke, has been reported

638 as expressed by ciliated cells and not club cells (31). Finally, the function of PIR in ciliated cells is less  
639 clear and its expression in ciliated cells has not been described previously.

640 As upregulation of SERGs in basal cells in the absence of other differentiated cell types was  
641 substantial, our results suggest that under certain conditions, basal cells are capable of xenobiotic  
642 metabolism and protection from oxidative stress. This may play an important role during bronchial  
643 epithelial injury for example, where, following luminal cell depletion, basal cells will be more exposed  
644 to inhaled toxic agents, but, as progenitor cells, indispensable for the necessary epithelial repair.  
645 Here, efficient upregulation of protection mechanisms against oxidative stress and mutagenic  
646 substances may be crucial for prevention of lung disease. In contrast, in an intact bronchial  
647 epithelium, basal cells may be protected from inhaled insults by club, ciliated and goblet cells, which,  
648 projecting into the lumen, provide the first-line defence.

649 A striking result of our study was that, in sharp contrast to wCS exposure, CSE failed to upregulate  
650 any of the SERGs when applied to fully differentiated pHBECs, even at an eight-fold higher dose  
651 (Figure 4). We chose this considerably higher non-toxic CSE concentration for this experiment  
652 because, even if for soluble chemicals the administered dose in general provides a reasonably  
653 accurate estimate of cell-delivered dose (101), CS components in CSE may be less bioavailable for the  
654 cells than the directly surface-applied wCS, as they will in part be bound to scavengers in the medium  
655 (*e.g.* proteins, free thiols, free amines). Therefore, ultimately, our observation that a substantially  
656 higher CSE dose still does not induce SERG expression, is more informative than if we had used the  
657 exact same dose. The drastically different efficacy in SERG expression between CSE and wCS most  
658 likely reflects the different constitutions of CSE and wCS in terms of cigarette smoke components: the  
659 water soluble components of wCS, which are retained in CSE, correspond to less than 40% of total  
660 wCS mass (102). Also, AhR signalling, which underlies induction of most of the SERGs, either directly  
661 or indirectly via Nrf2 signalling, is induced by highly hydrophobic compounds, a large part of which  
662 may not be retained in CSE (103). In addition, as mentioned above, toxicants in CSE may be partly  
663 scavenged by media components. Furthermore, even though cytotoxicity measurements reported by  
664 others (104) and our own previous measurements of mitochondrial superoxide and oxidative  
665 potential (21) indicate that CSE retains potency after freezing at  $-80^{\circ}\text{C}$ , the use of frozen instead of  
666 freshly produced CSE may have destroyed some of the active ingredients in CSE. Considering these  
667 discrepancies between CSE and wCS, it is again remarkable that basal cells alone are capable of  
668 strong upregulation of SERGs upon CSE treatment, even though the absolute concentration of PAH in  
669 CSE probably is relatively low, toxicants may be scavenged by media components, and freeze-  
670 thawing may have destroyed other active ingredients.

671 In conclusion, we have validated six different *in vitro* CS exposure settings of primary bronchial  
672 epithelial cells based on induction of carefully selected genes regulated by cigarette smoke exposure,  
673 collectively called SERGs, *in vivo*. Notably, quantification of CS dose for all exposure types allowed for  
674 dose-matched experiments applying comparable CS doses, and thus allowing for further  
675 standardization. Among these models, three quite dissimilar exposure types performed best: chronic  
676 basolateral CSE treatment of differentiating pHBEs significantly induced seven out of 10 SERGs,  
677 while acute CSE treatment of basal submerged pHBEs and wCS exposure of differentiated pHBEs  
678 significantly induced six out of 10 SERGs. Notably, acute CSE exposure of differentiated cells was  
679 ineffective, independent whether CSE was applied basolaterally or apically. Our results emphasize  
680 the need for validation of CS exposure models beyond assessment of viability and expression of the  
681 classical AhR-induced gene *CYP1A1*. While differentiated cells are most susceptible to wCS exposure,  
682 the exposure of submerged basal cells to CSE provides a technologically simpler, fast and efficient  
683 exposure setting to assess CS-regulated genes and may be particularly suited to assess regulation by  
684 CS under conditions of bronchial epithelial injury. CSE exposure of bronchial epithelial cells during the  
685 full period of differentiation on the other hand may be the model of choice when chronic CS  
686 exposure needs to be assessed. Overall, our findings provide important guidelines for the design of  
687 human cigarette smoke-induced *in vitro* models, in particular when using CSE instead of wCS.

#### 688 **SUPPLEMENTAL DATA**

689 Supplemental Tables S1-S4, and Supplemental Figures S1-S9 are available at:  
690 <https://doi.org/10.6084/m9.figshare.16713784>.

#### 691 **ACKNOWLEDGEMENTS**

692 We gratefully acknowledge the provision of human biomaterial and clinical data from the CPC-M  
693 bioArchive and its partners at the Asklepios Biobank Gauting, the Klinikum der Universität München  
694 and the Ludwig-Maximilians-Universität München. This work was supported by the Deutsche  
695 Forschungsgemeinschaft (DFG) within the Research Training Group GRK2338 (MM, grant to CASW),  
696 the Helmholtz Association, the German Center for Lung Research (DZL), and the Federal Institute for  
697 Risk Assessment (Bundesinstitut für Risikobewertung, BfR) within the Bf3R Research Funding  
698 Program in the area of 3R - Replacement, Reduction and Refinement (#1328-570, AC, grant to  
699 CASW). We gratefully acknowledge Mircea-Gabriel Stoleriu, Misako Nakayama and Annika Frank for  
700 providing their expertise and helpful discussions during this study, Hannah Marchi for statistical  
701 consulting, and Ceylan Onursal for help with artwork.

## 702 REFERENCES

703

- 704 1. **Chang SA.** Smoking and type 2 diabetes mellitus. *Diabetes Metab J* 36: 399-403, 2012.
- 705 2. **Durazzo TC, Mattsson N, Weiner MW, and Alzheimer's Disease Neuroimaging I.** Smoking  
706 and increased Alzheimer's disease risk: a review of potential mechanisms. *Alzheimers Dement* 10:  
707 S122-145, 2014.
- 708 3. **Jha P, MacLennan M, Chaloupka FJ, Yurekli A, Ramasundarahettige C, Palipudi K, Zatonksi  
709 W, Asma S, and Gupta PC.** Global Hazards of Tobacco and the Benefits of Smoking Cessation and  
710 Tobacco Taxes. In: *Cancer: Disease Control Priorities, Third Edition (Volume 3)*, edited by Gelband H,  
711 Jha P, Sankaranarayanan R, and Horton S. Washington (DC): 2015.
- 712 4. The top 10 causes of death. World Health Organisation. [https://www.who.int/news-](https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death)  
713 [room/fact-sheets/detail/the-top-10-causes-of-death](https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death). [20 Oct, 2020].
- 714 5. **Tam A, Wadsworth S, Dorscheid D, Man SF, and Sin DD.** The airway epithelium: more than  
715 just a structural barrier. *Thorax* 66: 255-273, 2011.
- 716 6. **Hiemstra PS, McCray PB, Jr., and Bals R.** The innate immune function of airway epithelial  
717 cells in inflammatory lung disease. *The European respiratory journal* 45: 1150-1162, 2015.
- 718 7. **Montoro DT, Haber AL, Biton M, Vinarsky V, Lin B, Birket SE, Yuan F, Chen S, Leung HM,  
719 Villoria J, Rogel N, Burgin G, Tsankov AM, Waghay A, Slyper M, Waldman J, Nguyen L, Dionne D,  
720 Rozenblatt-Rosen O, Tata PR, Mou H, Shivaraju M, Bihler H, Mense M, Tearney GJ, Rowe SM,  
721 Engelhardt JF, Regev A, and Rajagopal J.** A revised airway epithelial hierarchy includes CFTR-  
722 expressing ionocytes. *Nature* 560: 319-324, 2018.
- 723 8. **Davis JD, and Wypych TP.** Cellular and functional heterogeneity of the airway epithelium.  
724 *Mucosal Immunol* 2021.
- 725 9. **Schamberger AC, Staab-Weijnitz CA, Mise-Racek N, and Eickelberg O.** Cigarette smoke alters  
726 primary human bronchial epithelial cell differentiation at the air-liquid interface. *Sci Rep* 5: 8163,  
727 2015.
- 728 10. **Heijink IH, Brandenburg SM, Postma DS, and van Oosterhout AJ.** Cigarette smoke impairs  
729 airway epithelial barrier function and cell-cell contact recovery. *Eur Respir J* 39: 419-428, 2012.
- 730 11. **Zhang S, Li X, Xie F, Liu K, Liu H, and Xie J.** Evaluation of whole cigarette smoke induced  
731 oxidative stress in A549 and BEAS-2B cells. *Environ Toxicol Pharmacol* 54: 40-47, 2017.
- 732 12. **Pouwels SD, Zijlstra GJ, van der Toorn M, Hesse L, Gras R, Ten Hacken NH, Krysko DV,  
733 Vandenaabeele P, de Vries M, van Oosterhout AJ, Heijink IH, and Nawijn MC.** Cigarette smoke-  
734 induced necroptosis and DAMP release trigger neutrophilic airway inflammation in mice. *Am J Physiol  
735 Lung Cell Mol Physiol* 310: L377-386, 2016.
- 736 13. **Long C, Lai Y, Li T, Nyunoya T, and Zou C.** Cigarette smoke extract modulates *Pseudomonas*  
737 *aeruginosa* bacterial load via USP25/HDAC11 axis in lung epithelial cells. *Am J Physiol Lung Cell Mol  
738 Physiol* 318: L252-L263, 2020.
- 739 14. **Phillips J, Kluss B, Richter A, and Massey E.** Exposure of bronchial epithelial cells to whole  
740 cigarette smoke: assessment of cellular responses. *Altern Lab Anim* 33: 239-248, 2005.
- 741 15. **Nishida K, Brune KA, Putcha N, Mandke P, O'Neal WK, Shade D, Srivastava V, Wang M, Lam  
742 H, An SS, Drummond MB, Hansel NN, Robinson DN, and Sidhaye VK.** Cigarette smoke disrupts  
743 monolayer integrity by altering epithelial cell-cell adhesion and cortical tension. *Am J Physiol Lung  
744 Cell Mol Physiol* 313: L581-L591, 2017.
- 745 16. **Wu YP, Cao C, Wu YF, Li M, Lai TW, Zhu C, Wang Y, Ying SM, Chen ZH, Shen HH, and Li W.**  
746 Activating transcription factor 3 represses cigarette smoke-induced IL6 and IL8 expression via  
747 suppressing NF-kappaB activation. *Toxicol Lett* 270: 17-24, 2017.
- 748 17. **Thaikootathil JV, Martin RJ, Zdunek J, Weinberger A, Rino JG, and Chu HW.** Cigarette  
749 smoke extract reduces VEGF in primary human airway epithelial cells. *Eur Respir J* 33: 835-843, 2009.
- 750 18. **Jukosky J, Gosselin BJ, Foley L, Dechen T, Fiering S, and Crane-Godreau MA.** In vivo Cigarette  
751 Smoke Exposure Decreases CCL20, SLPI, and BD-1 Secretion by Human Primary Nasal Epithelial Cells.  
752 *Front Psychiatry* 6: 185, 2015.

- 753 19. **Yanagisawa S, Baker JR, Vuppusetty C, Koga T, Colley T, Fenwick P, Donnelly LE, Barnes PJ,**  
754 **and Ito K.** The dynamic shuttling of SIRT1 between cytoplasm and nuclei in bronchial epithelial cells  
755 by single and repeated cigarette smoke exposure. *PLoS One* 13: e0193921, 2018.
- 756 20. **Wong FH, AbuArish A, Matthes E, Turner MJ, Greene LE, Cloutier A, Robert R, Thomas DY,**  
757 **Cosa G, Cantin AM, and Hanrahan JW.** Cigarette smoke activates CFTR through ROS-stimulated  
758 cAMP signaling in human bronchial epithelial cells. *Am J Physiol Cell Physiol* 314: C118-C134, 2018.
- 759 21. **Andrault PM, Schamberger AC, Chazeirat T, Sizaret D, Renault J, Staab-Weijnitz CA, Hennen**  
760 **E, Petit-Courty A, Wartenberg M, Saidi A, Baranek T, Guyetant S, Courty Y, Eickelberg O, Lalmanach**  
761 **G, and Lecaille F.** Cigarette smoke induces overexpression of active human cathepsin S in lungs from  
762 current smokers with or without COPD. 317: L625-L638, 2019.
- 763 22. **Starke RM, Ali MS, Jabbour PM, Tjoumakaris SI, Gonzalez F, Hasan DM, Rosenwasser RH,**  
764 **Owens GK, Koch WJ, and Dumont AS.** Cigarette smoke modulates vascular smooth muscle  
765 phenotype: implications for carotid and cerebrovascular disease. *PLoS One* 8: e71954, 2013.
- 766 23. **van der Toorn M, Sewer A, Marescotti D, John S, Baumer K, Bornand D, Dulize R, Merg C,**  
767 **Corciulo M, Scotti E, Pak C, Leroy P, Guedj E, Ivanov N, Martin F, Peitsch M, Hoeng J, and Luettich K.**  
768 The biological effects of long-term exposure of human bronchial epithelial cells to total particulate  
769 matter from a candidate modified-risk tobacco product. *Toxicol In Vitro* 50: 95-108, 2018.
- 770 24. **Mathis C, Poussin C, Weisensee D, Gebel S, Hengstermann A, Sewer A, Belcastro V, Xiang Y,**  
771 **Ansari S, Wagner S, Hoeng J, and Peitsch MC.** Human bronchial epithelial cells exposed in vitro to  
772 cigarette smoke at the air-liquid interface resemble bronchial epithelium from human smokers.  
773 *American Journal of Physiology-Lung Cellular and Molecular Physiology* 304: L489-L503, 2013.
- 774 25. **Gindele JA, Kiechle T, Benediktus K, Birk G, Brendel M, Heinemann F, Wohnhaas CT,**  
775 **LeBlanc M, Zhang H, Strulovici-Barel Y, Crystal RG, Thomas MJ, Stierstorfer B, Quast K, and**  
776 **Schymeinsky J.** Intermittent exposure to whole cigarette smoke alters the differentiation of primary  
777 small airway epithelial cells in the air-liquid interface culture. *Sci Rep* 10: 6257, 2020.
- 778 26. **Gelbman BD, Heguy A, O'Connor TP, Zabner J, and Crystal RG.** Upregulation of pirin  
779 expression by chronic cigarette smoking is associated with bronchial epithelial cell apoptosis.  
780 *Respiratory Research* 8: 10, 2007.
- 781 27. **Wang R, Wang G, Ricard MJ, Ferris B, Strulovici-Barel Y, Salit J, Hackett NR, Gudas LJ, and**  
782 **Crystal RG.** Smoking-induced upregulation of AKR1B10 expression in the airway epithelium of healthy  
783 individuals. *Chest* 138: 1402-1410, 2010.
- 784 28. **Gower AC, Steiling K, Brothers JF, 2nd, Lenburg ME, and Spira A.** Transcriptomic studies of  
785 the airway field of injury associated with smoking-related lung disease. *Proc Am Thorac Soc* 8: 173-  
786 179, 2011.
- 787 29. **Van Dyck E, Nazarov PV, Muller A, Nicot N, Bosseler M, Pierson S, Van Moer K, Palissot V,**  
788 **Mascaux C, Knolle U, Ninane V, Nati R, Bremnes RM, Vallar L, Berchem G, and Schlessner M.**  
789 Bronchial airway gene expression in smokers with lung or head and neck cancer. *Cancer Medicine* 3:  
790 322-336, 2014.
- 791 30. **Yang CX, Shi H, Ding I, Milne S, Hernandez Cordero AI, Yang CWT, Kim EK, Hackett TL, Leung**  
792 **J, Sin DD, and Obeidat M.** Widespread Sexual Dimorphism in the Transcriptome of Human Airway  
793 Epithelium in Response to Smoking. *Sci Rep* 9: 17600, 2019.
- 794 31. **Duclos GE, Teixeira VH, Autissier P, Gesthalter YB, Reinders-Luinge MA, Terrano R, Dumas**  
795 **YM, Liu G, Mazzilli SA, Brandsma CA, van den Berge M, Janes SM, Timens W, Lenburg ME, Spira A,**  
796 **Campbell JD, and Beane J.** Characterizing smoking-induced transcriptional heterogeneity in the  
797 human bronchial epithelium at single-cell resolution. *Sci Adv* 5: eaaw3413, 2019.
- 798 32. **Spira A, Beane J, Shah V, Liu G, Schembri F, Yang X, Palma J, and Brody JS.** Effects of  
799 cigarette smoke on the human airway epithelial cell transcriptome. *Proc Natl Acad Sci U S A* 101:  
800 10143-10148, 2004.
- 801 33. **Harvey BG, Heguy A, Leopold PL, Carolan BJ, Ferris B, and Crystal RG.** Modification of gene  
802 expression of the small airway epithelium in response to cigarette smoking. *J Mol Med (Berl)* 85: 39-  
803 53, 2007.
- 804 34. **Beane J, Sebastiani P, Liu G, Brody JS, Lenburg ME, and Spira A.** Reversible and permanent  
805 effects of tobacco smoke exposure on airway epithelial gene expression. *Genome Biol* 8: R201, 2007.

- 806 35. **Shaykhiev R, Otaki F, Bonsu P, Dang DT, Teater M, Strulovici-Barel Y, Salit J, Harvey BG, and**  
807 **Crystal RG.** Cigarette smoking reprograms apical junctional complex molecular architecture in the  
808 human airway epithelium in vivo. *Cell Mol Life Sci* 68: 877-892, 2011.
- 809 36. **Walters MS, De BP, Salit J, Buro-Auriemma LJ, Wilson T, Rogalski AM, Lief L, Hackett NR,**  
810 **Staudt MR, Tilley AE, Harvey B-G, Kaner RJ, Mezey JG, Ashbridge B, Moore MAS, and Crystal RG.**  
811 Smoking accelerates aging of the small airway epithelium. *Respiratory Research* 15: 94, 2014.
- 812 37. **Murray LA, Dunmore R, Camelo A, Da Silva CA, Gustavsson MJ, Habel DM, Hackett TL,**  
813 **Hogaboam CM, Sleeman MA, and Knight DA.** Acute cigarette smoke exposure activates apoptotic  
814 and inflammatory programs but a second stimulus is required to induce epithelial to mesenchymal  
815 transition in COPD epithelium. *Respir Res* 18: 82, 2017.
- 816 38. **Voic H, Li X, Jang J-H, Zou C, Sundd P, Alder J, Rojas M, Chandra D, Randell S, Mallampalli**  
817 **RK, Tesfaigzi Y, Ryba T, and Nyunoya T.** RNA sequencing identifies common pathways between  
818 cigarette smoke exposure and replicative senescence in human airway epithelia. *BMC Genomics* 20:  
819 22, 2019.
- 820 39. **Comer DM, Elborn JS, and Ennis M.** Comparison of nasal and bronchial epithelial cells  
821 obtained from patients with COPD. *PLoS One* 7: e32924, 2012.
- 822 40. **Higham A, Bostock D, Booth G, Dungwa JV, and Singh D.** The effect of electronic cigarette  
823 and tobacco smoke exposure on COPD bronchial epithelial cell inflammatory responses. *Int J Chron*  
824 *Obstruct Pulmon Dis* 13: 989-1000, 2018.
- 825 41. **Bucchieri F, Marino Gammazza A, Pitruzzella A, Fucarino A, Farina F, Howarth P, Holgate ST,**  
826 **Zummo G, and Davies DE.** Cigarette smoke causes caspase-independent apoptosis of bronchial  
827 epithelial cells from asthmatic donors. *PLoS One* 10: e0120510, 2015.
- 828 42. **Liang Y, Tian L, Ho K-F, Ip MS-M, and Mak JC-W.** Comparisons on mitochondrial function  
829 following exposure of cigarette smoke extract and fine particulate matter in human bronchial  
830 epithelial cells. *Eur Respir J* 54: PA2436, 2019.
- 831 43. **Ito S, Ishimori K, and Ishikawa S.** Effects of repeated cigarette smoke extract exposure over  
832 one month on human bronchial epithelial organotypic culture. *Toxicol Rep* 5: 864-870, 2018.
- 833 44. **Schamberger AC, Mise N, Jia J, Genoyer E, Yildirim AO, Meiners S, and Eickelberg O.**  
834 Cigarette smoke-induced disruption of bronchial epithelial tight junctions is prevented by  
835 transforming growth factor-beta. *Am J Respir Cell Mol Biol* 50: 1040-1052, 2014.
- 836 45. **Bitterle E, Karg E, Schroepel A, Kreyling WG, Tippe A, Ferron GA, Schmid O, Heyder J,**  
837 **Maier KL, and Hofer T.** Dose-controlled exposure of A549 epithelial cells at the air-liquid interface to  
838 airborne ultrafine carbonaceous particles. *Chemosphere* 65: 1784-1790, 2006.
- 839 46. **Lenz AG, Karg E, Brendel E, Hinze-Heyn H, Maier KL, Eickelberg O, Stoeger T, and Schmid O.**  
840 Inflammatory and oxidative stress responses of an alveolar epithelial cell line to airborne zinc oxide  
841 nanoparticles at the air-liquid interface: a comparison with conventional, submerged cell-culture  
842 conditions. *Biomed Res Int* 2013: 652632, 2013.
- 843 47. **Serediuk V.** Wirkung von Zigarettenrauch auf Lungenzellen in vitro: Etablierung eines  
844 Zigarettenrauch-Zell-Expositionssystems (Unpublished Master's thesis). In: *Fakultät Biotechnologie*  
845 *und Bioinformatik Hochschule Weihenstephan-Triesdorf*, 2016.
- 846 48. **Boers JE, Ambergen AW, and Thunnissen FB.** Number and proliferation of basal and  
847 parabasal cells in normal human airway epithelium. *Am J Respir Crit Care Med* 157: 2000-2006, 1998.
- 848 49. **Boers JE, Ambergen AW, and Thunnissen FB.** Number and proliferation of clara cells in  
849 normal human airway epithelium. *Am J Respir Crit Care Med* 159: 1585-1591, 1999.
- 850 50. **Rogers DF.** The airway goblet cell. *The International Journal of Biochemistry & Cell Biology* 35:  
851 1-6, 2003.
- 852 51. **Srinivasan B, Kolli AR, Esch MB, Abaci HE, Shuler ML, and Hickman JJ.** TEER measurement  
853 techniques for in vitro barrier model systems. *J Lab Autom* 20: 107-126, 2015.
- 854 52. **Chen M, Yang T, Meng X, and Sun T.** Azithromycin attenuates cigarette smoke extract-  
855 induced oxidative stress injury in human alveolar epithelial cells. *Mol Med Rep* 11: 3414-3422, 2015.
- 856 53. **Ferraro M, Gjomarkaj M, Siena L, Di Vincenzo S, and Pace E.** Formoterol and fluticasone  
857 propionate combination improves histone deacetylation and anti-inflammatory activities in bronchial

858 epithelial cells exposed to cigarette smoke. *Biochim Biophys Acta Mol Basis Dis* 1863: 1718-1727,  
859 2017.

860 54. **Qin H, Gao F, Wang Y, Huang B, Peng L, Mo B, and Wang C.** Nur77 promotes cigarette  
861 smoke-induced autophagic cell death by increasing the dissociation of Bcl2 from Beclin-1. *Int J Mol*  
862 *Med* 44: 25-36, 2019.

863 55. **Amatngalim GD, van Wijck Y, de Mooij-Eijk Y, Verhoosel RM, Harder J, Lekkerkerker AN,**  
864 **Janssen RA, and Hiemstra PS.** Basal cells contribute to innate immunity of the airway epithelium  
865 through production of the antimicrobial protein RNase 7. *J Immunol* 194: 3340-3350, 2015.

866 56. **Benam KH, Novak R, Nawroth J, Hirano-Kobayashi M, Ferrante TC, Choe Y, Prantil-Baun R,**  
867 **Weaver JC, Bahinski A, Parker KK, and Ingber DE.** Matched-Comparative Modeling of Normal and  
868 Diseased Human Airway Responses Using a Microengineered Breathing Lung Chip. *Cell Syst* 3: 456-  
869 466 e454, 2016.

870 57. **Thorne D, Kilford J, Payne R, Adamson J, Scott K, Dalrymple A, Meredith C, and Dillon D.**  
871 Characterisation of a Vitrocell(R) VC 10 in vitro smoke exposure system using dose tools and  
872 biological analysis. *Chem Cent J* 7: 146, 2013.

873 58. **Robinson RJ, and Yu CP.** Deposition of cigarette smoke particles in the human respiratory  
874 tract. *Aerosol Sci Technol* 34: 202-215, 2001.

875 59. **Paur HR, Cassee FR, Teeguarden J, Fissan H, Diabate S, Aufderheide M, Kreyling WG,**  
876 **Hanninen O, Kasper G, Riediker M, Rothen-Rutishauser B, and Schmid O.** In-vitro cell exposure  
877 studies for the assessment of nanoparticle toxicity in the lung-A dialog between aerosol science and  
878 biology. *J Aerosol Sci* 42: 668-692, 2011.

879 60. **Parrish ME, Lyons-Hart JL, and Shafer KH.** Puff-by-puff and intrapuff analysis of cigarette  
880 smoke using infrared spectroscopy. *Vib Spectrosc* 27: 29-42, 2001.

881 61. **Balashazy I, Hofmann W, and Heistracher T.** Local particle deposition patterns may play a  
882 key role in the development of lung cancer. *J Appl Physiol (1985)* 94: 1719-1725, 2003.

883 62. **Heyder J.** Deposition of inhaled particles in the human respiratory tract and consequences  
884 for regional targeting in respiratory drug delivery. *Proc Am Thorac Soc* 1: 315-320, 2004.

885 63. **Brody JS.** Transcriptome alterations induced by cigarette smoke. *Int J Cancer* 131: 2754-2762,  
886 2012.

887 64. **Balásházy I, Hofmann W, and Heistracher T.** Computation of local enhancement factors for  
888 the quantification of particle deposition patterns in airway bifurcations. *J Aerosol Sci* 30: 185-203,  
889 1999.

890 65. **Mossina A, Lukas C, Merl-Pham J, Uhl FE, Mutze K, Schamberger A, Staab-Weijnitz C, Jia J,**  
891 **Yildirim AO, Konigshoff M, Hauck SM, Eickelberg O, and Meiners S.** Cigarette smoke alters the  
892 secretome of lung epithelial cells. *Proteomics* 17: 2017.

893 66. **Tatsuta M, Kan OK, Ishii Y, Yamamoto N, Ogawa T, Fukuyama S, Ogawa A, Fujita A,**  
894 **Nakanishi Y, and Matsumoto K.** Effects of cigarette smoke on barrier function and tight junction  
895 proteins in the bronchial epithelium: protective role of cathelicidin LL-37. *Respir Res* 20: 251, 2019.

896 67. **Faiz A, Heijink IH, Vermeulen CJ, Guryev V, van den Berge M, Nawijn MC, and Pouwels SD.**  
897 Cigarette smoke exposure decreases CFLAR expression in the bronchial epithelium, augmenting  
898 susceptibility for lung epithelial cell death and DAMP release. *Sci Rep* 8: 12426, 2018.

899 68. **Simet SM, Sisson JH, Pavlik JA, Devasure JM, Boyer C, Liu X, Kawasaki S, Sharp JG, Rennard**  
900 **SI, and Wyatt TA.** Long-term cigarette smoke exposure in a mouse model of ciliated epithelial cell  
901 function. *Am J Respir Cell Mol Biol* 43: 635-640, 2010.

902 69. **Pickett G, Seagrave J, Boggs S, Polzin G, Richter P, and Tesfaigzi Y.** Effects of 10 cigarette  
903 smoke condensates on primary human airway epithelial cells by comparative gene and cytokine  
904 expression studies. *Toxicol Sci* 114: 79-89, 2010.

905 70. **Zevin S, and Benowitz NL.** Drug Interactions with Tobacco Smoking. *Clin Pharmacokinet* 36:  
906 425-438, 1999.

907 71. **Guerrina N, Traboulsi H, Eidelman DH, and Baglolle CJ.** The Aryl Hydrocarbon Receptor and  
908 the Maintenance of Lung Health. *Int J Mol Sci* 19: 2018.

- 909 72. **Nebert DW, Roe AL, Dieter MZ, Solis WA, Yang Y, and Dalton TP.** Role of the aromatic  
910 hydrocarbon receptor and [Ah] gene battery in the oxidative stress response, cell cycle control, and  
911 apoptosis. *Biochem Pharmacol* 59: 65-85, 2000.
- 912 73. **Murray GI, Melvin WT, Greenlee WF, and Burke MD.** Regulation, Function, and Tissue-  
913 Specific Expression of Cytochrome P450 CYP1B1. *Annu Rev Pharmacool Toxicol* 41: 297-316, 2001.
- 914 74. **Miao W, Hu L, Scrivens PJ, and Batist G.** Transcriptional regulation of NF-E2 p45-related  
915 factor (NRF2) expression by the aryl hydrocarbon receptor-xenobiotic response element signaling  
916 pathway: direct cross-talk between phase I and II drug-metabolizing enzymes. *J Biol Chem* 280:  
917 20340-20348, 2005.
- 918 75. **Rangasamy T, Cho CY, Thimmulappa RK, Zhen L, Srisuma SS, Kensler TW, Yamamoto M,  
919 Petrache I, Tudor RM, and Biswal S.** Genetic ablation of Nrf2 enhances susceptibility to cigarette  
920 smoke-induced emphysema in mice. *The Journal of Clinical Investigation* 114: 1248-1259, 2004.
- 921 76. **Cho HY, Reddy SP, Debiase A, Yamamoto M, and Kleeberger SR.** Gene expression profiling  
922 of NRF2-mediated protection against oxidative injury. *Free Radic Biol Med* 38: 325-343, 2005.
- 923 77. **Penning TM.** Aldo-Keto Reductase Regulation by the Nrf2 System: Implications for Stress  
924 Response, Chemotherapy Drug Resistance, and Carcinogenesis. *Chem Res Toxicol* 30: 162-176, 2017.
- 925 78. **Nishinaka T, Miura T, Okumura M, Nakao F, Nakamura H, and Terada T.** Regulation of aldo-  
926 keto reductase AKR1B10 gene expression: Involvement of transcription factor Nrf2. *Chem Biol*  
927 *Interact* 191: 185-191, 2011.
- 928 79. **Lou H, Du S, Ji Q, and Stolz A.** Induction of *AKR1C2* by Phase II Inducers:  
929 Identification of a Distal Consensus Antioxidant Response Element Regulated by NRF2. *Mol*  
930 *Pharmacol* 69: 1662-1672, 2006.
- 931 80. **Thimmulappa RK, Mai KH, Srisuma S, Kensler TW, Yamamoto M, and Biswal S.** Identification  
932 of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide  
933 microarray. *Cancer Res* 62: 5196-5203, 2002.
- 934 81. **Chan K, and Kan YW.** Nrf2 is essential for protection against acute pulmonary injury in mice.  
935 *Proc Natl Acad Sci U S A* 96: 12731-12736, 1999.
- 936 82. **Brzóska K, Stępkowski TM, and Kruszewski M.** Basal PIR expression in HeLa cells is driven by  
937 NRF2 via evolutionary conserved antioxidant response element. *Mol Cell Biochem* 389: 99-111, 2014.
- 938 83. **Namani A, Matiur Rahaman M, Chen M, and Tang X.** Gene-expression signature regulated  
939 by the KEAP1-NRF2-CUL3 axis is associated with a poor prognosis in head and neck squamous cell  
940 cancer. *BMC Cancer* 18: 46, 2018.
- 941 84. **Morel Y, Mermod N, and Barouki R.** An autoregulatory loop controlling CYP1A1 gene  
942 expression: role of H<sub>2</sub>O<sub>2</sub> and NFI. *Mol Cell Biol* 19: 6825-6832, 1999.
- 943 85. **Dietrich C.** Antioxidant Functions of the Aryl Hydrocarbon Receptor. *Stem Cells International*  
944 2016: 7943495, 2016.
- 945 86. **Di YP, Zhao J, and Harper R.** Cigarette smoke induces MUC5AC protein expression through  
946 the activation of Sp1. *J Biol Chem* 287: 27948-27958, 2012.
- 947 87. **Di Sano C, D'Anna C, Ferraro M, Chiappara G, and Pace E.** Notch-1 expression is increased by  
948 cigarette smoke exposure and its activation up-regulates ki67, PCNA proliferative markers and actin  
949 polymerizations in bronchial epithelial cells. *Eur Respir J* 54: PA2399, 2019.
- 950 88. **Ou-Yang HF, Wu CG, Qu SY, and Li ZK.** Notch signaling downregulates MUC5AC expression in  
951 airway epithelial cells through Hes1-dependent mechanisms. *Respiration* 86: 341-346, 2013.
- 952 89. **Yin SJ, Chou CF, Lai CL, Lee SL, and Han CL.** Human class IV alcohol dehydrogenase: kinetic  
953 mechanism, functional roles and medical relevance. *Chem Biol Interact* 143-144: 219-227, 2003.
- 954 90. **Jelski W, Chrostek L, Szmítkowski M, and Laszewicz W.** Activity of class I, II, III, and IV alcohol  
955 dehydrogenase isoenzymes in human gastric mucosa. *Dig Dis Sci* 47: 1554-1557, 2002.
- 956 91. **Duester G, Shean ML, McBride MS, and Stewart MJ.** Retinoic acid response element in the  
957 human alcohol dehydrogenase gene ADH3: implications for regulation of retinoic acid synthesis. *Mol*  
958 *Cell Biol* 11: 1638-1646, 1991.
- 959 92. **Balmer JE, and Blomhoff R.** Gene expression regulation by retinoic acid. *J Lipid Res* 43: 1773-  
960 1808, 2002.

- 961 93. **Fulcher ML, Gabriel S, Burns KA, Yankaskas JR, and Randell SH.** Well-Differentiated Human  
962 Airway Epithelial Cell Cultures. In: *Human Cell Culture Protocols*, edited by Picot J. Totowa, NJ:  
963 Humana Press, 2005, p. 183-206.
- 964 94. **Rayner RE, Makena P, Prasad GL, and Cormet-Boyaka E.** Optimization of Normal Human  
965 Bronchial Epithelial (NHBE) Cell 3D Cultures for in vitro Lung Model Studies. *Sci Rep* 9: 500, 2019.
- 966 95. **Leung JM, Yang CX, Tam A, Shaipanich T, Hackett T-L, Singhera GK, Dorscheid DR, and Sin**  
967 **DD.** ACE-2 Expression in the Small Airway Epithelia of Smokers and COPD Patients: Implications for  
968 COVID-19. *Eur Respir J* 2000688, 2020.
- 969 96. **Ross D, and Siegel D.** NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions  
970 and pharmacogenetics. *Methods Enzymol* 382: 115-144, 2004.
- 971 97. **Siegel D, Franklin WA, and Ross D.** Immunohistochemical detection of NAD(P)H:quinone  
972 oxidoreductase in human lung and lung tumors. *Clin Cancer Res* 4: 2065-2070, 1998.
- 973 98. **Carolan BJ, Heguy A, Harvey BG, Leopold PL, Ferris B, and Crystal RG.** Up-regulation of  
974 expression of the ubiquitin carboxyl-terminal hydrolase L1 gene in human airway epithelium of  
975 cigarette smokers. *Cancer Res* 66: 10729-10740, 2006.
- 976 99. **Osaka H, Wang YL, Takada K, Takizawa S, Setsuie R, Li H, Sato Y, Nishikawa K, Sun YJ,**  
977 **Sakurai M, Harada T, Hara Y, Kimura I, Chiba S, Namikawa K, Kiyama H, Noda M, Aoki S, and Wada**  
978 **K.** Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron. *Hum Mol*  
979 *Genet* 12: 1945-1958, 2003.
- 980 100. **Brinkmann K, Zigrino P, Witt A, Schell M, Ackermann L, Broxtermann P, Schull S, Andree M,**  
981 **Coutelle O, Yazdanpanah B, Seeger JM, Klubertz D, Drebbler U, Hacker UT, Kronke M, Mauch C,**  
982 **Hoppe T, and Kashkar H.** Ubiquitin C-terminal hydrolase-L1 potentiates cancer chemosensitivity by  
983 stabilizing NOXA. *Cell Rep* 3: 881-891, 2013.
- 984 101. **Teeguarden JG, Hinderliter PM, Orr G, Thrall BD, and Pounds JG.** Particokinetics in vitro:  
985 dosimetry considerations for in vitro nanoparticle toxicity assessments. *Toxicol Sci* 95: 300-312, 2007.
- 986 102. **Schumacher JN, Green CR, Best FW, and Newell MP.** Smoke composition. An extensive  
987 investigation of the water-soluble portion of cigarette smoke. *J Agric Food Chem* 25: 310-320, 1977.
- 988 103. **Larigot L, Juricek L, Dairou J, and Coumoul X.** AhR signaling pathways and regulatory  
989 functions. *Biochim Open* 7: 1-9, 2018.
- 990 104. **Bourgeois JS, Jacob J, Garewal A, Ndahayo R, and Paxson J.** The Bioavailability of Soluble  
991 Cigarette Smoke Extract Is Reduced through Interactions with Cells and Affects the Cellular Response  
992 to CSE Exposure. *PLOS ONE* 11: e0163182, 2016.
- 993

994 **FIGURE LEGENDS**

995 **Figure 1. Differentiation of primary bronchial epithelial cells at the air-liquid-interface. (A)**  
996 Schematic overview of expansion and differentiation of bronchial epithelial cells. During the  
997 expansion phase, basal cells were cultured on regular tissue culture plastic, followed by seeding on  
998 transwells. Upon reaching confluency, the apical medium was removed to create an air-liquid  
999 interface, which was maintained throughout differentiation into a pseudostratified epithelium for 28  
1000 days. **(B)** Representative immunofluorescent stainings for cell-type specific markers including tumor  
1001 protein 63 (p63), acetylated tubulin (acTub), Club cells 10 kDa secretory protein (CC10), and mucin  
1002 5AC (MUC5AC) for basal, ciliated, club, and goblet cells, respectively, confirmed differentiation into a  
1003 full-blown bronchial epithelium over time. Results shown are representative for n=4.  
1004 **(C)** Quantification of all main bronchial epithelial cell types from immunofluorescent stainings  
1005 demonstrate increase of ciliated, club, and goblet cells at the expense of basal cells. Results shown  
1006 are derived from n=4 (independent donors) and given as mean  $\pm$  SD. **(D)** Epithelial barrier integrity, as  
1007 assessed by transepithelial electrical resistance (TEER), stabilized over the course of differentiation.  
1008 Results shown are derived from n=5 (independent donors) and given as mean  $\pm$  SD. Scale bar, 40 $\mu$ m.

1009 **Figure 2. Exposure of basal primary human bronchial epithelial cells under submerged conditions**  
1010 **to cigarette smoke extract (CSE) resulted in upregulation of six out of nine smoke exposure**  
1011 **regulated genes (SERGs). (A)** Experimental set-up. Non-differentiated phBECs were exposed to 0, 2.5,  
1012 5.0, 10 and 20% CSE under submerged conditions for 24 h, followed by collection of RNA and protein.  
1013 **(B)** Results of RT-qPCR are presented as fold change of 9 genes relative to control normalized to 1  
1014 (red line). Mucin 5AC (MUC5AC) was not expressed under these conditions and thus not included.  
1015 Genes are shown in order of regulation strength in current smokers from highest (left) to lowest  
1016 (right) fold change (see Table 1). Hydroxymethylbilane synthase transcript (HMBS) was used as  
1017 internal reference gene. Statistical analysis was assessed by repeated measures ANOVA with  
1018 Bonferroni correction for multiple comparisons (\*, p<0.05; \*\*, p<0.01; \*\*\*, p<0.001). **(C)**  
1019 Representative Western Blots for four selected SERGs show dose-dependent regulation also on  
1020 protein level.  $\beta$ -actin (ACTB) was used as loading control. Results shown are based on n = 4  
1021 (independent donors) and given as mean  $\pm$  SD.

1022 **Figure 3. Chronic basolateral exposure of primary human bronchial epithelial cells during the**  
1023 **complete course of differentiation resulted in significant upregulation of seven out of 10 smoke**  
1024 **exposure regulated genes (SERGs). (A)** Experimental set-up. PhBECs were chronically exposed to 5%  
1025 CSE in the basolateral compartment from day 0 to day 28 of differentiation. **(B)** Results of RT-qPCR  
1026 are presented as fold change relative to control normalized to 1 (red line). Genes are shown in order  
1027 of regulation strength in current smokers from highest (left) to lowest (right) fold change (see Table

1028 1). WD repeat-containing protein 89 (WDR89) transcript was used as internal reference gene.  
1029 Statistical analysis was assessed by repeated measures ANOVA followed by Bonferroni correction for  
1030 multiple comparisons ( $p < 0.05$ ; \*,  $p < 0.05$ ; \*\*,  $p < 0.01$ ; \*\*\*,  $p < 0.001$ ). (C) In agreement with transcript  
1031 data, representative Western Blots for four selected SERGs show regulation on protein level for  
1032 ALDH3A1 and NQO1, but less prominently for AKR1B10 and AKR1C1.  $\beta$ -actin (ACTB) was used as  
1033 loading control. Results shown are based on  $n = 5$  (independent donors) and given as mean  $\pm$  SD.

1034 **Figure 4. Short acute apical exposure of differentiated primary human bronchial epithelial cells**  
1035 **with whole cigarette smoke (wCS) and cigarette smoke extract (CSE) using comparable CS**  
1036 **particulate doses resulted in significant upregulation of six out of 10 smoke exposure regulated**  
1037 **genes (SERGs) for wCS, but none for CSE. (A)** Experimental set-up. Fully differentiated phBECs were  
1038 either exposed apically to 200  $\mu$ l of 40% CSE for 5 min or to 5 min exposure to wCS generated by 3  
1039 cm of a research grade cigarette followed by culture of cells for 24 h and sample collection for mRNA  
1040 and protein analysis. (B) Results of RT-qPCR are presented as fold change of 10 genes relative to  
1041 control normalized to 1 (red line). WD repeat-containing protein 89 (WDR89) transcript was used as  
1042 internal reference gene. Statistical analyses was performed using two tailed student's *t*-test (\*,  
1043  $p < 0.05$ ; \*\*,  $p < 0,01$ ; \*\*\*,  $p < 0.001$ ). (C) Representative Western Blots for 4 selected SERGs show no  
1044 upregulation on protein level for CSE, but moderate upregulation for all 4 for wCS.  $\beta$ -actin (ACTB) was  
1045 used as loading control. (D) Representative immunofluorescent stainings demonstrate increases in  
1046 the number of AKR1C1<sup>+</sup>, NQO1<sup>+</sup>, PIR<sup>+</sup>. and UCHL1<sup>+</sup> cells. Scale bar 40  $\mu$ m. Results shown are based on  
1047  $n = 5$  (independent donors) and given as mean  $\pm$  SD.

1048 **Figure 5. Acute apical exposure of differentiated primary human epithelial cells with cigarette**  
1049 **smoke extract (CSE) resulted in significant upregulation of one out of 10 smoke exposure regulated**  
1050 **gene (SERGs). (A)** Experimental set-up. Fully differentiated phBECs were exposed apically to 200  $\mu$ l of  
1051 0% 3%, 6%, 12% CSE for 24 h followed by collection of cells for mRNA and protein analysis. (B) Results  
1052 of RT-qPCR are presented as fold change of 10 genes relative to control normalized to 1 (red line).  
1053 Genes are shown in order of regulation strength in current smokers from highest (left) to lowest  
1054 (right) fold change (see Table 1). Hypoxanthine-guanine phosphoribosyltransferase (HPRT) was used  
1055 as internal reference gene. Statistical analysis was assessed by repeated measures ANOVA with  
1056 Bonferroni correction for multiple comparisons (\*,  $p < 0.05$ ). (C) Representative Western Blots for four  
1057 selected SERGs show no regulation on protein level.  $\beta$ -actin (ACTB) was used as loading control.  
1058 Results shown are based on  $n = 4$  (independent donors) and given as mean  $\pm$  SD.

1059 **Figure 6. Acute basolateral exposure of fully differentiated primary human bronchial epithelial cells**  
1060 **resulted in significant upregulation of one out of 10 smoke exposure regulated genes (SERGs). (A)**  
1061 Experimental setup. Fully differentiated phBECs were exposed basolaterally to 5 % cigarette smoke

1062 extract (CSE) for 24 h followed by collection of cells for mRNA and protein analysis. **(B)** Results of RT-  
1063 qPCR (n=5) are presented as fold change of 10 genes relative to control normalized to 1 (dotted line).  
1064 Genes are shown in order of regulation strength in current smokers from highest (left) to lowest  
1065 (right) fold change (see Table 1). Polyubiquitin-C (UBC) was used as a housekeeper gene. Statistical  
1066 analyses were performed using paired two tailed *t*-test ( $p < 0.05$ ). **(C)** Western Blots (n=5) are shown  
1067 for 4 assessed genes.  $\beta$ -actin (ACTB) was used as loading control. Results shown are based on n= 5  
1068 (independent donors) and given as mean  $\pm$  SD.

1069 **Figure 7. Immunofluorescent stainings for assessment of cell-type-specific expression of selected**  
1070 **smoke exposure regulated genes (SERGs).** Representative immunofluorescent stainings (n=3) of  
1071 primary human bronchial epithelial cells (phBECs) exposed to whole cigarette smoke (wCS)  
1072 demonstrate expression of all selected SERGs in basal cells (p63<sup>+</sup> cells). In addition, NQO1, PIR, and  
1073 UCHL1 are expressed by ciliated cells (acTub<sup>+</sup> cells), and AKR1C1 by club cells (CC10<sup>+</sup> cells). Scale bars,  
1074 50 $\mu$ m and 20 $\mu$ m. For more co-stainings with cell-type-specific markers, the reader is referred to  
1075 supplementary figure S6. Results shown are based on n= 3 (independent donors).


1076

1077


1078

1079


A




B




C




D




A







B




C









A




B




C




A




B



C









DAPI



**Table 1. List of genes selected as reference genes for smoke exposure based on their upregulated expression in current smokers relative to non-smokers, termed smoke exposure regulated genes (SERGs) in this study. Average fold changes are derived from microarray datasets GSE994, GSE4498, GSE7895, GSE20257 and GSE52237, and given as +/- SD.**

#	Gene name	Protein	Fold change $\pm$ SD
1	<b>CYP1B1</b>	Cytochrome P450 1B1	33 $\pm$ 30
2	<b>AKR1B10</b>	Aldo-keto reductase 1B10	22 $\pm$ 3.6
3	<b>CYP1A1</b>	Cytochrome P450 1A1	13 $\pm$ 11
4	<b>UCHL1</b>	Ubiquitin carboxyl-terminal hydrolase isozyme L1	10 $\pm$ 7.2
5	<b>ALDH3A1</b>	Aldehyde dehydrogenase 3A1	7.2 $\pm$ 1.4
6	<b>ADH7</b>	Alcohol dehydrogenase class 4	5.7 $\pm$ 2.5
7	<b>MUC5AC</b>	Mucin 5AC	3.9 $\pm$ 1.3
8	<b>AKR1C1</b>	Aldo-keto reductase family 1 member C1	4.0 $\pm$ 0.7
9	<b>NQO1</b>	NAD(P)H dehydrogenase [quinone] 1	3.9 $\pm$ 0.4
10	<b>PIR</b>	Pirin	3.3 $\pm$ 0.7

**Table 2. Overview of assessed cigarette smoke extract (CSE) and whole cigarette smoke (wCS) models.** For details on the respective models, please refer to the relevant figures and text passages in the Material and Methods section.

#	Model	CSE concentrations	CS dose [ $\mu\text{g}/\text{cm}^2$ ]	Volume delivered [ $\mu\text{l}/\text{cm}^2$ ]	(Exposure) and Incubation time	Starvation	Refers to	Graphical outline
1	Acute submerged CSE exposures (n=4)	2.5%, 5%, 10%, 20%	6.6, 13, 26, 53	210	24 h	No	Figure 2	
2	Chronic basolateral CSE exposure (n=5)	5%	62	890	28 days	No	Figure 3	
3	Short acute apical CSE exposure (n=5)	40%	100	180	(5 min) 24 h	No	Figure 4	
4	ALICE-Smoke (n=5)	N/A	12±1.5	N/A	(5 min) 24 h	No	Figure 4	
5	Acute apical exposure (n=4)	3%, 6%, 12%	7.5, 15, 30	180	24 h	Yes/No	Figure 5, S8	
6	Acute basolateral CSE exposure (n=5)	5%	62	890	24 h	No	Figure 6	



**Table 3. Summary of SERG mRNA fold changes in the tested models, compared to upregulation by CS in current smokers (top row). Statistically significant results ( $p < 0.05$ ) are given in bold and the number of significantly upregulated genes is given the last column.**

	Dose per area [ $\mu\text{g}/\text{cm}^2$ ]	CYP1B1	AKR1B10	CYP1A1	UCL1	ALDH3A1	ADH7	MUC5AC	AKR1C1	NQO1	PIR	No.
Healthy smokers <sup>a</sup>	N/A	<b>33</b>	<b>22</b>	<b>13</b>	<b>10</b>	<b>7.2</b>	<b>5.7</b>	<b>3.9</b>	<b>4.0</b>	<b>3.9</b>	<b>3.3</b>	<b>10</b>
Chronic basolateral CSE exposure <sup>b</sup>	<b>62</b>	<b>4.9</b>	<b>2.6</b>	<b>56</b>	1.8	<b>1.8</b>	1.4	1.7	<b>1.8</b>	<b>1.5</b>	<b>1.6</b>	<b>7</b>
ALICE-Smoke exposure	<b>12</b>	<b>74</b>	<b>6.6</b>	<b>42215</b>	<b>32</b>	2.4	0.8	0.6	<b>8.0</b>	<b>3.3</b>	2.0	<b>6</b>
Acute submerged basal cells CSE exposure <sup>c</sup>	<b>56</b>	2.0	<b>4.0</b>	<b>6.4</b>	<b>4.2</b>	3.1	0.4	N/A	<b>7.1</b>	<b>4.2</b>	<b>2.7</b>	<b>6</b>
Acute basolateral CSE exposure	<b>62</b>	2.1	2.2	<b>5.4</b>	0.9	1.1	1.2	0.7	1.1	0.9	1.1	<b>1</b>
Acute apical CSE exposure w/starvation <sup>d</sup>	<b>30</b>	1.5	1.1	<b>11</b>	1.0	1.5	1.3	1.3	1.2	1.0	1.4	<b>1</b>
Acute apical CSE exposure w/o starvation <sup>d</sup>	<b>30</b>	2.3	1.4	<b>12</b>	1.6	1.7	1.2	1.7	1.5	1.2	1.3	<b>1</b>
Short acute apical CSE exposure	<b>100</b>	0.8	0.9	1.8	1.1	1.2	0.9	1.8	1.2	1.0	1.0	<b>0</b>

<sup>a</sup> mRNA fold changes in bronchial cells brushed from healthy active smokers, obtained from transcriptomic data, references in Table 1

<sup>b</sup> Fold changes shown for day 28. For *CYP1A1* significance was obtained at days 7 and 21, for *AKR1C1* at days 7 and 14, and for *PIR* at day 21 (see Fig. 3)

<sup>c</sup> Fold changes shown for 20% CSE

<sup>d</sup> Fold changes shown for 12% CSE